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ABSTRACT

Disclosed herein is a simple method for the treatment of
antigen-deficiency diseases, by orally administering to a
subject a therapeutically effective amount of the deficient
antigen, wherein the antigen is not present in a liposome. In
one embodiment, the method increases hemostasis in a

Subject having hemophilia A or B, by orally administering to
the hemophiliac a therapeutically effective amount of the
appropriate clotting factor other than in a liposome, Sufi
cient to induce oral tolerance and Supply exogenous clotting
factor to the subject.
28 Claims, 7 Drawing Sheets
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ORAL TREATMENT OF HEMOPHILA

Mol. Ther. 3:225-35; Bristol et al. 2001. Hum. Gene Ther.
12:1651-61; Geet al. 2001. Blood 97:3733-7: Brinkhous et

CROSS REFERENCE TO RELATED
APPLICATION

This is a national stage under 35 U.S.C. S371 of Interna
tional Application No. PCT/US02/24544, filed Aug. 2, 2002,
and claims the benefit of U.S. Provisional application No.
60/310,150, filed Aug. 3, 2001, which is hereby incorporated
by reference in its entirety.
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FIELD

This disclosure relates to methods for treating a subject
Suffering from an antigen-deficiency which causes a disease,
by orally administering a therapeutically effective amount of
the deficient antigen to the Subject, Sufficient to induce oral
tolerance and relieve symptoms of the disease. In one
example, the disclosure relates to oral administration of
clotting factor VIII or IX for treating hemophilia A and B,
respectively.

15

BACKGROUND

Hemophilia A and B, caused respectively by decreased
levels of clotting factor VIII (F.VIII) and IX (FIX) levels in
peripheral blood, are the most common severe inherited
bleeding disorders. Although purified clotting factors from
human plasma can be infused into these patients to prevent
or treat bleeding episodes, this poses the risk of spreading of
diseases such as Creutzfled-Jakob disease, HIV, and hepa
titis C. Although recombinant clotting factor preparations
are available, the supply is insufficient to cover the world
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wide demand.

As an alternative to generating recombinant clotting fac
tors in cell culture, the use of transgenic animals as biore
actors for the production of clinically useful quantities of
proteins has been proposed. The transgenic animal expresses
the desired protein in a body fluid, such as milk, from which
the protein can readily be isolated. Transgenic pigs that
secrete F.VIII (U.S. Pat. No. 5,880,327 to Lubon et al.) or
FIX (Van Cott et al. 1999. Genet. Anal. 15:155-60) in their
milk were generated using gene constructs that have regu
latory sequences from the gene for mouse whey acidic
protein (the 4.2 kb 5’ promoter of WAP), in combination
with the cDNA sequence encoding human F.VIII or F.IX.
F.VIII pigs secrete 2.7 g/ml of human F.VIII into milk
(Paleyanda et al. 1997. Nat. Biotech. 15:971), while F.IX
pigs secrete 2.5 g/L of human F.IX into milk, and the factor
is biologically active as measured by an activated partial
thromboplastin time assay (APTT).
Therefore, large amounts of functional protein can be
obtained from FIX pigs, which is purified from the milk, and
Subsequently administered intravenously (i.v.) to a hemo
philiac patient. However, it has previously been thought that
oral administration of F.VIII or F.IX results in degradation
and/or inactivation of the protein due to the acidic and
enzymatic composition of the stomach. For example, U.S.
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Pat. No. 4,348,384 to Horikoshi et al. teaches the adminis

tration of an oral composition containing purified F.VIII or
FIX encapsulated in a liposome along with a protease
inhibitor, for the purpose of evading gastric inactivation of
the therapeutic protein.
One complication that results from i.v. administration of
F.VIII or F.IX is that up to 25% of hemophiliacs develop
inhibitors, such as antibodies against F.VIII or F.IX that
inactivate their procoagulant activity (Fields et al. 2000.
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al. 1996. Blood 88:2603-10). Most inhibitory antibodies
develop in severely affected patients who have little or no
circulating F.IX or F.VIII antigen due to genetic deletion.
However, patients with a family history of inhibitor devel
opment, severe disease, older age or higher numbers of
clotting factor replacement episodes, also have a higher
incidence of developing these inhibitors (Roberts. 1997.
Inhibitors and their management. In Hemophilia & Other
inherited bleeding disorders. Rizza & Lowe, eds. W B
Saunders Company Ltd., London, p. 365.). The inhibitors
can completely inhibit the activity of infused clotting factor
and make further treatment difficult.

One means of reducing clotting factor antibodies is the
induction of immune tolerance to the clotting factors. For
example, Roberts (JAMA 259:84-5, 1988) reviews studies in
which F.VIII was injected at high concentrations. Although
some studies reported that the level of anti-factor VIII
antibodies decreased, due to the high doses required, the
method was never widely used because it was prohibitively
expensive. Oral administration of F.VIII as a means to
prevent the formation of anti-F.VIII antibodies has also been
attempted, with mixed results. Oral administration of puri
fied F.VIII to newborn mice did not suppress induction of
anti-F.VIII antibodies (Kaplan et al. 2000. Semin. Thromb.
Hemost. 26:173-8). Oral administration of purified F.VIII to
one of three patients with acquired hemophilia did reduce
the amount of anti-F.VIII antibodies (Lindgren et al. 2000.
Thromb. Haemost. 83:632-3). However, there are no teach
ings that oral administration of clotting factors alone can be
used to treat hemophilia which is caused by inadequate
expression of a clotting factor.
Attempts to induce stable production of the missing
clotting factors by gene therapy using injections of trans
fected myoblasts have also been hampered by the host
immune system which, not being tolerant of the missing
factor, generates a strong rejection response when intro
duced (Fields et al. 2000. Mol. Ther. 3:225-35). Thus,
inhibitory antibodies to the factors and vigorous T cell
responses to the genetically transfected cells are major
hurdles to successful treatment of hemophilia.
Another disadvantage to introduction of a foreign gene
through the use of a viral vector, is the possibility of an
elicited immune response against the vector and/or the
transgene product For example, intramuscular (i.m.) injec
tion of an adenoviral vector expressing human F.IX into the
hind limbs of hemophiliac mice results in a CTL response
against FIX, and destruction of the transduced cells,
whereas i.m. injection of a less immunogenic vector (adeno
associated virus, AAV) expressing human F.IX results in
long-term persistence of the transduced cells and an absence
of CTL to FIX (Roberts. 1997. Inhibitors and their man
agement. In Hemophilia & Other inherited bleeding disor
ders. Rizza & Lowe, eds., W B Saunders Company Ltd.,
London, p. 365.). However, in both cases formation of
antibodies neutralizes F.IX activity. The same problem
exists in the canine model of hemophilia B, where anti-F.IX
antibodies neutralize F.IX activity after gene therapy with
FIX (Evans et al. 1989. Proc. Natl. Acad. Sci. U S A.
86:10095-9; Mauser et al. 1996. Blood. 88:3451-5; Herzog
et al. 1999. Nat. Med. 5:56-63; and Kay et al. 2000. Nat.
Genet. 24:257-261).
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FIGS. 8A and 8B are dot plots showing that orally
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SUMMARY OF THE DISCLOSURE

Although potentially large amounts of functional protein
can be obtained from F.IX pigs, the current teaching has
been to purify the factor from the milk, and subsequently
administer it intravenously (i.v.) to a hemophiliac patient.
However, it would be advantageous if the protein could be
delivered orally, as oral administration is more easily
handled than injection, and may eliminate the need for
protein purification. In addition, it would be beneficial if oral
tolerance to clotting factors could be induced by oral admin
istration of the clotting factor.
Disclosed herein is a method for treating an antigen
deficiency disease by orally administering a therapeutically
effective amount of the deficient antigen. In one non-limiting
example, the method is a method for increasing hemostasis
in a subject having a hemophilia caused by inadequate
expression of a clotting factor, by orally administering a
therapeutically effective amount of a clotting factor other
than in a liposome. In another example, the method is a
method for decreasing the symptoms associated with Gau
cher disease (such as decreasing hepatosplenomegaly and
improving bone marrow involvement), in a Subject having
Gaucher disease caused by decreased expression of acid
beta-glucosidase, by orally administering a therapeutically
effective amount of a acid beta-glucosidase.

administered F.VIII remains functional, whether adminis
tered in water or in cow's milk.
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administration of F.IX can be achieved whether adminis

tered in water or in milk, but that it is more effective if given
in milk.
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milk.

FIGS. 6A and 6B are a graph and a dot plot, respectively,
showing that oral feeding of transgenic pig milk containing
F.IX results in the presence of F.IX in the blood.
FIG. 7A is a dot plot showing that orally administered
F.IX remains functional, and corrects the bleeding defect in
hemophilia B mice.
FIG. 7B is a graph showing that orally administered FIX
remains functional, and corrects the bleeding defect in
hemophilia B mice fed F.IX milk for 2 months.

The following explanations of terms and methods are
provided to better describe the present disclosure and to
guide those of ordinary skill in the art in the practice of the
present disclosure. As used herein and in the appended
claims, the singular forms “a” or “an or “the include plural
references unless the context clearly dictates otherwise. For
example, reference to “a protein’ includes a plurality of such
proteins and reference to “the antibody' includes reference
to one or more antibodies and equivalents thereof known to
those skilled in the art, and so forth.

30

mice that had not been immunized.

FIGS. 5A and 5B are graphs comparing the proliferative
response against sheep casein, in lambs fed (A) sheep milk
or (B) cow milk.
FIG. 5C is a dot plot comparing the serum IgG titer to
sheep casein in lambs raised on sheep milk compared to cow

DETAILED DESCRIPTION OF SEVERAL
EMBODIMENTS

Abbreviations and Terms

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is a dot-plot comparing the footpad Swelling in
mice fed OVA prior to injection (0.1-10 mg OVA) with
control mice not fed OVA prior to injection (0 mg OVA).
FIG. 1B shows three dot-plots comparing the amount of
IL-4, TGF-B, and IFN-Y production in mice fed OVA prior
to injection, with control mice not fed OVA (water) prior to
injection.
FIG. 1C is a graph comparing the amount of T-cell
proliferation in mice fed OVA prior to injection (0.001-10
mg OVA) with control mice not fed OVA prior to injection
(0 mg OVA).
FIGS. 2A and 2B are graphs comparing the amount of
T-cell proliferation in (A) normal and (B) hemophilia B mice
fed human F.IX prior to injection, with control mice not fed
human F.IX prior to injection.
FIG. 2C is a graph comparing the level of IgA produced
in F.IX-fed hemophilia B mice to unfed normal mice.
FIGS. 3A and 3B are dot plots showing (A) IgG1 and (B)
IgG2a antibody responses to hF.IX.
FIG. 4 is a dot plot showing that orally tolerized hemo
philia B mice show little evidence of inhibitors, as their
bleeding times are only slightly longer than those of infused

FIG. 8C is a dot plot showing that immunization follow
ing oral administration of F.VIII does not inhibit F.VIII fed
Subsequent to the immunization.
FIG. 8D is a dot plot showing IgG1 and IgG2a antibody
responses to hF.VIII.
FIGS. 9A and 9B are graphs comparing the T cell
response in mice fed F.IX in water or milk showing that oral
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Unless explained otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood to one of ordinary skill in the art to which this
disclosure belongs.
Antigen: A Substance capable of being the target of
inducing a specific immune response.
Antigen-Deficiency Disease: A disease in which a subject
has an antigen deficiency, such as a protein, which causes the
disease. Examples of antigen-deficiency diseases include,
but are not limited to clotting disorders such as hemophilia
A and B (caused by a deficiency of clotting factor VIII and
IX, respectively), Von Willebrand’s disease (caused by a
moderate-to-severe factor VIII deficiency, low-levels of
factor VIII-related antigen, and insufficient von Willebrand
factor); and diabetes (caused by a deficiency of insulin).
Other examples of antigen deficiency diseases include,
but are not limited to: strokes or heart attacks (deficiency of
tissue plasminogen activator); emphysema (deficiency of
alpha-1-antitrypsin); Gaucher disease (deficiency of B-glu
cosidase), Pompe's disease (deficiency of alpha-1,4-glucosi
dase); purpura fulminans neonatalis, warfin-induced skin
necrosis, heparin-induced thrombocytopenia, septic shock,
and for fibrinolytic therapy (deficiency of protein C) (also
see U.S. Pat. No. 5,589,604).
In a particular embodiment, the treatment of such diseases
can be achieved by orally administering the deficient antigen
to a Subject having the disease.
Anti-immune therapy: Administration of agents to a Sub
ject having an autoimmune disease to reduce the immune
response against normal body tissue while leaving intact the
immune response against micro-organisms and abnormal
tissues. Examples of agents used to reduce the immune
response include, but are not limited to: corticosteroids and
immunosuppressant medications (including prednisolone,
cyclophosphamide or azathioprine) or cytotoxic agents such
as cytotoxan or methotrexate.
Activated partial thromboplastin time (APTT) Assay: An
assay that measures the time it takes plasma to clot. APTT

US 7,220,718 B2
5
is the period required for clot formation in recalcified blood
plasma after contact activation and the addition of platelet
Substitutes (e.g., brain cephalin or similar phospholipids). In
normal individuals, the APTT is about 30-40 seconds, and

the PTT (therapeutic level) is 60 to 70 seconds. A prolonged
APTT can indicate a deficiency of a number of clotting
factors including Factors XII, XI, IX, VIII, X, V, and II, and
fibrinogen.
Bleeding Time Assay: An assay used to measure the
amount of time it takes for a subject’s blood to clot. A blood
pressure cuff is placed on the upper arm and inflated. Two

10

incisions are made on the lower arm. These are about 10 mm

(less than /2 inch) long and 1 mm deep (just deep enough to
cause minimal bleeding). The blood pressure cuff is imme
diately deflated. Blotting paper is touched to the cuts every
30 seconds until the bleeding stops. The length of time it
takes for the cuts to stop bleeding is recorded.
In normal, non-hemophiliacs, bleeding stops within about
one to ten minutes and may vary from lab to lab, depending
on how the assay is measured. In contrast, severe hemo
philiacs having less than 1% of normal levels of the appro
priate clotting factor have a whole blood clotting time of
greater than 60 minutes.
In mice, the bleeding time is assayed by transecting the tip
of the tail and periodically touching a blotting paper until a
clot is formed at the tip of the tail. Normal bleeding time is
between 2-4 minutes. In contrast, hemophiliac mice having
less than 1% of normal levels of the appropriate clotting
factor have a bleeding time of greater than 15 minutes (see
FIGS. 7A, 7B, 8A and 8B).
cDNA (complementary DNA): A piece of DNA lacking
internal, non-coding segments (introns) and regulatory
sequences which determine transcription. cDNA can be
synthesized in the laboratory by reverse transcription from
messenger RNA extracted from cells.
Chemical synthesis: An artificial means by which one can
make a protein or peptide. A synthetic protein or peptide is
one made by Such artificial means.
Clotting disorder: A disease resulting in a defect in
hemostasis in a subject. In one embodiment, it is a disease
of the blood clotting (coagulation) system in which bleeding
is prolonged due to inadequate clotting factors in the blood,
for example inadequate expression of the clotting factor,
Such as inadequate expression due to a genetic abnormality.
Normal blood hemostasis is a complex process involving as
many as 20 different plasma proteins, known as clotting
factors. Normally, a complex chemical process occurs using
these clotting factors to form a substance called fibrin that
stops bleeding. When certain coagulation factors are defi
cient or missing, the process does not occur normally.
Bleeding problems can range from mild to severe.
Some bleeding disorders are present at birth and in some
instances are inherited disorders. Specific examples include,
but are not limited to: hemophilia A, hemophilia B, protein
C deficiency, and Von Willebrand’s disease. Some bleeding
disorders are developed during certain illnesses (such as
Vitamin K deficiency, severe liver disease), or treatments
(such as use of anticoagulant drugs or prolonged use of
antibiotics).
Clotting factor: Includes any protein which promotes
proper hemostasis. In one embodiment, a clotting factor is
factor VIII (F.VIII) or factor IX (FIX), or a variant or
fragment thereof which retains its hemostatic activity, for
example as measured using an APTT assay or a bleeding
time assay. In another embodiment, when orally adminis
tered in a therapeutically effective amount, the clotting
factor increases hemostasis in a subject Suffering from a
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6
clotting disorder, Such as hemophilia. In a particular embodi
ment, a clotting factor is a recombinant clotting factor,
wherein expression of a DNA encoding the clotting factor in
a mammal results in the presence of the recombinant clotting
factor protein in the milk of the transgenic mammal.
Comprises: A term that means “including.” For example,
“comprising A or B' means including A or B, or both A and
B, unless clearly indicated otherwise.
Deletion: The removal of a sequence of a nucleic acid, for
example DNA, the regions on either side being joined
together.
DNA: Deoxyribonucleic acid. DNA is a long chain poly
mer which comprises the genetic material of most living
organisms (some viruses have genes comprising ribonucleic
acid, RNA). The repeating units in DNA polymers are four
different nucleotides, each of which comprises one of the
four bases, adenine, guanine, cytosine and thymine bound to
a deoxyribose Sugar to which a phosphate group is attached.
Triplets of nucleotides, referred to as codons, in DNA
molecules code for amino acid in a polypeptide. The term
codon is also used for the corresponding (and complemen
tary) sequences of three nucleotides in the mRNA into which
the DNA sequence is transcribed.
Enhance: To improve the quality, amount, or strength of
Something. In one embodiment, a therapy enhances or
increases hemostasis in a Subject (Such as a hemophiliac) if
the subject is more effective at blood clotting (for example,
their blood clotting time decreases). Such enhancement can
be measured using the methods disclosed herein, for
example determining the bleeding time of a subject using an
APTT or bleeding time assay.
Factor VIII (F.VIII) F.VIII is a protein required for the
efficient clotting of blood, and functions in coagulation as a
cofactor in the activation of factor X by factor IX. A
concentration of about 100 ng/ml for F.VIII in the blood is
considered in the normal range. Deficiency of F.VIII is
associated with hemophilia A, and severe forms of the
disease can result when a subject has less than about 1% of
the normal amount of F.VIII (i.e. less than about 1 ng of
F.VIII per ml of blood). F.VIII is synthesized as a 2351
amino acid single chain precursor protein, which is pro
teolytically processed. The human factor VIII gene (186,000
base-pairs) consists of 26 exons ranging in size from 69 to
3,106 bp and introns as large as 32.4 kilobases (kb).
Examples of F.VIII nucleic acid and protein sequences,
including variants and fragments thereof, and sequences
from different organisms, are publicly available on Genbank
(for example see Accession Nos: KO1740, M14113, and
E00527 (human): AF016234 (canine); and L05573
(mouse)).
Gaucher Disease: An autosomal-recessive disorder that
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results from defective activity of acid B-glucosidase. Dis
ease variants are classified based on the absence or presence
and severity of neuronopathic involvement. Enzyme therapy
is currently the treatment of choice in significantly affected
patients. For example, cerezyme, a recombinantly produced
mannose-terminated (macrophage-targeted) acid B-glucosi
dase, is currently used to diminish hepatosplenomegaly and
improve bone marrow involvement and hematologic find
ings. However, it is possible that oral administration of
B-glucosidase using the methods disclosed herein, can be
used to alleviate one or more symptoms associated with
Gaucher disease described below.

65

Type 2 Gaucher disease is a rare, severe CNS disease that
leads to death by 2 years of age.
Type 3 Gaucher disease has highly variable manifesta
tions in the CNS and viscera. It can present in early

US 7,220,718 B2
7
childhood with rapidly progressive, massive visceral disease
and slowly progressive to static CNS involvement; in ado
lescence with dementia; or in early adulthood with rapidly
progressive, uncontrollable myoclonic seizures and mild
visceral disease. Visceral disease in type 3 is nearly identical
to that in type 1, but is generally more severe. Early CNS
findings may be limited to defects in lateral gaze tracking,
which may remain static for decades. Mental retardation can
be slowly progressive or static.
Type 1 Gaucher disease is a highly variable nonneurono
pathic disease. Younger patients tend to have a greater
degree of hepatosplenomegaly and accompanying blood
cytopenias. Older patients have a greater tendency for
chronic bone disease. Hepatosplenomegaly occurs in virtu
ally all symptomatic patients and can be minor or massive.
Accompanying anemia and thrombocytopenia are variable
and not linearly related to liver or spleen volume. Severe
liver dysfunction is unusual, though minor liver function
abnormalities are common. Splenic infarctions can resemble
an acute abdomen. Pulmonary hypertension and alveolar

8
FIX is less than about 1% of the normal concentration of

F.IX (i.e. less than about 0.01-0.05ug F.IX per ml of blood).
Canine F.IX possesses 86% identity at the amino-acid level
with human F.IX (Evans et al. 1989. Blood 74:207-12). F.IX
nucleic acid and protein sequences, including variants and
fragments thereof, and sequences from different organisms,
are publicly available (for example see Kurachi et al., 1982.
Proc. Nat. Acad. Sci. U.S.A. 79(21):6461-4; Genbank Acces
sion Nos: JOO136, XM 045316, KO2402, J00137, and
10

M11309 (human) and M21757 and M33826 (canine)).
Hemophilia: A blood coagulation disorder caused by a
deficient clotting factor activity, which decreases hemosta
sis. Severe forms result when the concentration of clotting

15

the clotting factor in a normal Subject. In some subjects,
hemophilia is due to a genetic mutation which results in
impaired expression of a clotting factor. In others, hemo
philia is an auto-immune disorder, referred to as acquired
hemophilia, in which the antibodies which are generated
against a clotting factor in a subject result in decreased

factor is less than about 1% of the normal concentration of

hemostasis.

Gaucher cell accumulation are uncommon, but life-threat

ening.
Though it is more common in adult patients, clinically
evident skeletal disease in children can be devastating,
resulting in massive destruction of the axial and peripheral
skeleton. All patients with Gaucher disease have non-uni
form infiltration of bone marrow by lipid-laden macroph
ages, termed Gaucher cells. This can lead to marrow packing
with Subsequent infarction, ischemia, necrosis, and cortical
bone destruction. Bone marrow involvement spreads from
proximal to distal in the limbs and can involve the axial
skeleton extensively, causing vertebral collapse. In addition
to bone marrow involvement, bone remodeling is defective,
with loss of total bone calcium leading to osteopenia,
osteonecrosis, avascular infarction, and vertebral compres
sion fractures and spinal cord involvement. Aseptic necrosis

25

an inherited sex-linked recessive trait with the defective
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of the femoral head is common, as is fracture of the femoral
neck.

Affected patients experience chronic, ill-defined bone
pain that can be debilitating. Some patients have one or more

ferred when the mutations are known. Four common muta
tions account for ~90 to 95% of the mutations in affected

patients: N370S (1226G), 84GG (a G insertion at cDNA
position 84), L444P (1448C), and IVS-2 (an intron 2 splice
junction mutation). Genotype/phenotype studies indicate a
significant correlation, though not absolute, between disease
type and severity and the acid B-glucosidase genotype.
Factor IX (F.IX): F.IX is a vitamin K-dependent protein
required for the efficient clotting of blood, and functions in
coagulation as an activator of factor X. A concentration of
about 1-5 lug/ml of F.IX in the blood is considered in the
normal range. Deficiency of F.IX is associated with hemo
philia B, and severe cases result when the concentration of

gene located on the X chromosome, and this disease is
therefore generally found only in males. The severity of
symptoms can vary with this disease, and the severe forms
become apparent early on. Bleeding is the hallmark of the
disease and typically occurs when a male infant is circum
cised. Additional bleeding manifestations make their appear
ance when the infant becomes mobile. Mild cases may go
unnoticed until later in life when they occur in response to
Surgery or trauma. Internal bleeding may happen anywhere,
and bleeding into joints is common.
Hemophiliac: A Subject having a hemophilia.
Hemostasis: Arrest of bleeding blood by blood clot for
mation. When hemostasis is increased, it is increased rela

40

“bone crises' in their lifetimes that are associated with

localized, excruciating pain, and, on occasion, local
erythema, fever, and leukocytosis. Any bone can be
involved, though the femurs and vertebral bodies are
affected most often. These crises represent acute infarctions
of bone, as evidenced in nuclear scans by localized absent
uptake of pyrophosphate agents. X-rays are usually negative
initially but may show lytic lesions 4 to 6 months after the
acute phase.
The diagnosis of Gaucher disease is established by dem
onstrating decreased acid B-glucosidase activity (0 to 20%
of normal) in nucleated cells. The enzyme is not present in
bodily fluids. The sensitivity of enzyme testing is poor for
detecting heterozygous carriers; molecular testing is pre

Hemophilia A results from a deficiency of functional
clotting factor VIII (F.VIII), while hemophilia B results from
a deficiency of functional clotting factor IX (F.IX). These
conditions which are due to a genetic mutation are caused by
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tive to hemostasis in a Subject prior to orally administering
a therapeutically effective amount of the appropriate clotting
factor to the Subject. In one embodiment, when hemostasis
increases in a Subject with hemophilia, the blood clotting
time decreases. Blood clotting time is the length of time it
takes for peripheral blood to clot using an activated partial
thromboplastin time assay (APTT, see EXAMPLE 9) or by
measuring bleeding time (see above and EXAMPLE 5). In
a particular embodiment, the blood clotting time decreases
by at least 50%, for example at least 60%, at least 70%, at
least 75%, at least 80%, at least 90%, at least 95%, at least

98%, at least 99% or even about 100% (i.e. the blood
clotting time is similar to what is observed for a normal
subject) when compared to the blood clotting time of the
Subject prior to orally administering to the Subject a thera
peutically effective amount of the appropriate clotting factor.
In yet another embodiment, the blood clotting time in the
affected subject is corrected to about 90% of a normal
subject, for example to about 95%, for example about 100%,
after oral administration of a therapeutically effective
amount of the appropriate clotting factor.
Impaired Expression: Decreased expression of a DNA or
protein resulting in a deficiency of the protein in a Subject.
Such a protein deficiency may cause disease in the Subject.
Isolated: An isolated nucleic acid has been substantially
separated or purified away from other nucleic acid
sequences in the cell of the organism in which the nucleic
acid naturally occurs, i.e., other chromosomal and extrach

US 7,220,718 B2
romosomal DNA and RNA. The term "isolated

thus

encompasses nucleic acids purified by standard nucleic acid
purification methods. The term also embraces nucleic acids
prepared by recombinant expression in a host cell as well as
chemically synthesized nucleic acids.
Liposome: A closed, solvent-filled vesicle bounded by a
single bilayer of phospholipids, which is impermeable to
many Substances. In one embodiment, a liposome has the
properties described in U.S. Pat. No. 4,348,384 to Horikoshi
et al. (herein incorporated by reference).

10

Mammal: This term includes both human and non-human

mammals. Similarly, the terms “patient,” “subject,” and
“individual' includes both human and veterinary subjects.
Examples of mammals include, but are not limited to:
humans, pigs, cows, goats, cats, dogs, rabbits and mice.

15

Normal Cells: Non-disease cells. In one embodiment,

normal cells are cells obtained from a healthy subject, for
example as compared to a hemophilic or diabetic Subject.
Normal Subject: A subject who does not have an antigen
deficiency disease. For example, a Subject who does not
have hemophilia A or B.
Oligonucleotide: A linear polynucleotide sequence of up
to about 200 nucleotide bases in length, for example a
polynucleotide (such as DNA or RNA) which is at least
about 6 nucleotides, for example at least 15, 50, 100 or 200
nucleotides long.
Operably linked: A first nucleic acid sequence is operably
linked with a second nucleic acid sequence when the first
nucleic acid sequence is placed in a functional relationship
with the second nucleic acid sequence. For instance, a
promoter is operably linked to a coding sequence if the
promoter affects the transcription or expression of the cod
ing sequence. Generally, operably linked DNA sequences
are contiguous and, where necessary to join two protein
coding regions, in the same reading frame.
ORF (open reading frame): A series of nucleotide triplets
(codons) coding for amino acids without any termination
codons. These sequences are usually translatable into a
peptide.
Oral administration: A method of delivering an agent to a
Subject by mouth. In one embodiment, oral administration is
achieved by feeding the agent to the Subject. In a particular
embodiment, the agent is an antigen, such as a protein, for
example F.VIII or F.IX. The agent can be delivered with one
or more pharmaceutically acceptable carriers which are not
liposomes. In addition, the agent and one or more therapeu
tically effective pharmaceutical compounds can be admin
istered concurrently or separately.
Oral tolerance: A method of downregulating an immune
response in a Subject by orally administering an antigen (i.e.
by feeding) to the subject. Oral tolerance is characterized by
decreased levels of systemic antibody production, as well as
decreased delayed type hypersensitivity responses (DTH), T
cell proliferation, cytotoxic responses and graft rejection
(Alpan et al. 2001. J. Immunol. 166:4843-52; Chen et al.
1995. Nature 376:177-80; Weiner. 1997. Imm. Today. 7:335
44; Sayegh et al. 1992. Transplantation. 53:163-6).
The tolerogenic effect due to administration of high doses
oral antigen is deletion of antigen-specific T cells by apop
tosis (Weiner. 1997. Imm. Today, 7:335-44). Administration
of low doses of oral antigen induces a Switch in effector class
such that Th1 type responses (DTH, cytotoxicity, graft
rejection and complement fixing antibodies) are Supplanted
by Th3 type responses (the production of IL-4, IL 10, TGF-B
and, occasionally, secretory IgA) (Weiner. 1997. Imm.
Today. 7:335-44). Low dose oral tolerance reduces the

25

10
severity of EAE (Fields et al. 2000. Molecular Therapy.
3:225-35) and enables the acceptance of foreign transplants.
Promoter: An array of nucleic acid control sequences
which direct transcription of a nucleic acid. A promoter
includes necessary nucleic acid sequences near the start site
of transcription, Such as, in the case of a polymerase II type
promoter, a TATA element. A promoter also optionally
includes distal enhancer or repressor elements which can be
located as much as several thousand base pairs from the start
site of transcription.
Purified: The term purified does not require absolute
purity; rather, it is intended as a relative term. Thus, for
example, a purified clotting factor preparation is one in
which the factor is more pure than the factor in its natural
environment within a cell. For example, a preparation of a
clotting factor protein is purified if the protein represents at
least 50%, for example at least 70%, of the total protein
content of the preparation. Methods for purification of
proteins and nucleic acids are well known in the art.
Examples of methods that can be used to purify an antigen,
Such as a clotting factor include, but are not limited to the
methods disclosed in Sambrook et al. (Molecular Cloning:
A Laboratory Manual, Cold Spring Harbor, N.Y., 1989, Ch.
17); U.S. Pat. No. 6,005,082 to Smeds; EP 0294.910 to van
Ooyen et al.:
Recombinant: A recombinant nucleic acid is one that has
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a sequence that is not naturally occurring or has a sequence
that is made by an artificial combination of two otherwise
separated segments of sequence. This artificial combination
is often accomplished by chemical synthesis or, more com
monly, by the artificial manipulation of isolated segments of
nucleic acids, e.g., by genetic engineering techniques. A
recombinant protein is one that results from expressing a
recombinant nucleic acid encoding the protein.
RT: Room temperature
Sample: Biological samples containing genomic DNA,
cDNA, RNA, or protein obtained from the cells of a subject,
Such as those present in peripheral blood, urine, saliva, tissue
biopsy, Surgical specimen, fine needle aspriates, amniocen
tesis samples and autopsy material.
Sequence identity/similarity: The identity/similarity
between two or more nucleic acid sequences, or two or more
amino acid sequences, is expressed in terms of the identity
or similarity between the sequences. Sequence identity can
be measured in terms of percentage identity; the higher the
percentage, the more identical the sequences are. Sequence
similarity can be measured in terms of percentage similarity
(which takes into account conservative amino acid substi
tutions); the higher the percentage, the more similar the
Sequences are.

Methods of alignment of sequences for comparison are
well known in the art. Various programs and alignment
algorithms are described in: Smith & Waterman, Adv. Appl.
Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol.
55

60

48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci.
USA 85:2444, 1988: Higgins & Sharp, Gene, 73:237-44,
1988: Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et
al., Nuc. Acids. Res. 16:10881-90, 1988; Huang et al.
Computer Appls. in the Biosciences 8, 155-65, 1992; and
Pearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschulet

al., J. Mol. Biol. 215:403-10, 1990, presents a detailed
consideration of sequence alignment methods and homology
calculations.
65

The NCBI Basic Local Alignment Search Tool (BLAST)
(Altschulet al., J. Mol. Biol. 215:403-10, 1990) is available
from several sources, including the National Center for
Biological Information (NCBI, National Library of Medi
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cine, Building 38A, Room 8N805, Bethesda, Md. 20894)
and on the Internet, for use in connection with the sequence
analysis programs blastp, blastin, blastX, thlastn and thlastX.

12
In other examples, it is an amount effective to increase
hemostasis by more than a desired amount.
In one embodiment, the therapeutically effective amount
also includes a quantity of clotting factor (such as a clotting
factor protein or nucleic acid) sufficient to achieve a desired
effect in a Subject being treated. For instance, these can be
an amount necessary to improve signs and/or symptoms a
disease Such as hemophilia, for example by increasing

Additional information can be found at the NCBI web site.

For comparisons of amino acid sequences of greater than
about 30 amino acids, the Blast 2 sequences function is
employed using the default BLOSUM62 matrix set to
default parameters, (gap existence cost of 11, and a per
residue gap cost of 1). When aligning short peptides (fewer
than around 30 amino acids), the alignment should be
performed using the Blast 2 sequences function, employing
the PAM30 matrix set to default parameters (open gap 9.
extension gap 1 penalties). Proteins with even greater simi
larity to the reference sequence will show increasing per
centage identities when assessed by this method. Such as at

hemostasis.
10

15

least 70%, 75%, 80%, 85%, 90%, 95%, or even 99%

sequence identity. When less than the entire sequence is
being compared for sequence identity, homologs will typi
cally possess at least 75% sequence identity over short
windows of 10-20 amino acids, and can possess sequence
identities of at least 85%, 90%. 95% or 98% depending on
their identity to the reference sequence. Methods for deter
mining sequence identity over Such short windows are

other embodiment, it is a concentration of F.VIII, when

described at the NCBI web site.

Protein homologs are typically characterized by posses

25

sion of at least 70%, such as at least 75%, 80%, 85%, 90%,

95% or even 98% sequence identity, counted over the
full-length alignment with the amino acid sequence using
the NCBI Basic Blast 2.0, gapped blastp with databases such
as the nr or Swissprot database. Queries searched with the
blastin program are filtered with DUST (Hancock and Arm
strong, 1994, Comput. Appl. Biosci. 10:67-70). Other pro
grams use SEG.
One of skill in the art will appreciate that these sequence
identity ranges are provided for guidance only; it is possible
that strongly significant homologs could be obtained that fall
outside the ranges provided. Provided herein are the peptide
homologs described above, as well as nucleic acid mol
ecules that encode such homologs.
Nucleic acid sequences that do not show a high degree of
identity may nevertheless encode identical or similar (con
served) amino acid sequences, due to the degeneracy of the
genetic code. Changes in a nucleic acid sequence can be
made using this degeneracy to produce multiple nucleic acid
molecules that all encode Substantially the same protein.
Such homologous peptides can, for example, possess at least
75%, 80%, 90%. 95%, 98%, or 99% sequence identity
determined by this method. When less than the entire
sequence is being compared for sequence identity, homologs
can, for example, possess at least 75%, 85% 90%. 95%, 98%
or 99% sequence identity over short windows of 10-20
amino acids. Methods for determining sequence identity
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F.VIII or F.IX, effective to increase hemostasis, such as in a

Subject to whom it is administered. Such as a hemophiliac.

orally administered, which results in a blood concentration
of greater than about 1 ng F.VIII per ml blood, for example
greater than about 10 ng per ml, for example about 100 ng
per ml. In yet another embodiment, it is a concentration of
F.IX, when orally administered, which results in a blood
concentration of greater than about 0.01-0.05ug F.IX per ml
blood, for example greater than about 0.1-0.5 ug per ml, for
example about 1-5 ug per ml.
The methods disclosed herein have equal application in
medical and veterinary settings. Therefore, the general term
“subject being treated is understood to include all animals
(e.g. humans, apes, dogs, cats, horses, and cows) that require
an increase in the desired biological effect, Such as enhanced
hemostasis Susceptible to clotting factor-mediated modula
tion.

40

45

50

over such short windows can be found at the NCBI web site.

One of skill in the art will appreciate that these sequence
identity ranges are provided for guidance only; it is possible
that significant homologs or other variants can be obtained
that fall outside the ranges provided.
Subject: Living multicellular vertebrate organisms, a cat
egory which includes, both human and veterinary Subjects
for example, mammals, rodents, and birds.
Therapeutically Effective Amount: An amount sufficient
to achieve a desired biological effect, for example an amount
that is effective to increase hemostasis. In particular
examples, it is a concentration of clotting factor. Such as

An effective amount of a clotting factor can be adminis
tered in a single dose, or in several doses, for example daily,
during a course of treatment. However, the effective amount
of clotting factor will be dependent on the source of clotting
factor administered (i.e. clotting factor isolated from a blood
sample versus recombinant clotting factor expressed in
milk), the subject being treated, the severity and type of the
condition being treated, and the manner of administration
clotting factor. For example, a therapeutically effective
amount of clotting factor can vary from about 0.01 mg/kg
body weight to about 5 g/kg body weight, for example, at
least 5 mg/kg daily, for example at least 50 mg/kg daily. In
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Therapeutically effective dose: A dose of antigen suffi
cient to increase the amount of that antigen in a Subject to
whom it is administered, resulting in a regression of a
pathological condition, or which is capable of relieving
signs or symptoms caused by the condition. In a particular
embodiment, it is a dose of clotting factor Sufficient to
increase hemostasis in a hemophiliac.
Transformed: A transformed cell is a cell into which has

been introduced a nucleic acid molecule by molecular
biology techniques. As used herein, the term transformation
encompasses all techniques by which a nucleic acid mol
ecule might be introduced into Such a cell, including trans
fection with viral vectors, transformation with plasmid vec
tors, and introduction of naked DNA by electroporation,
lipofection, and particle gun acceleration.
Transgenic Cell: Transformed cells which contain for
eign, non-native DNA.
Transgenic mammal: Transformed mammals which con
tain foreign, non-native DNA. In one embodiment, the
non-native DNA is an antigen, such as human F.VIII or
human F.IX. In a particular embodiment, a transgenic mam
mal expresses a recombinant clotting factor in its milk. In
yet another embodiment, the transgenic animal is a pig
expressing recombinant human F.VIII or F.IX in its milk.
One skilled in the art will understand that any mammal can
be used, including, but not limited to pigs, cows, goats,
sheep, rats, mice, rabbits, dogs, cats, and primates.
Variants or fragments or fusion proteins: The production
of protein which is orally administered can be accomplished
in a variety of ways (for example see EXAMPLES 15 and

US 7,220,718 B2
13
16). DNA sequences which encode for a protein or fusion
protein, or a fragment or variant of a protein (for example a
fragment or variant having 80%, 90% or 95% sequence
identity to a blood clotting factor) can be engineered to allow
the protein to be expressed in eukaryotic cells or organisms,
bacteria, insects, and/or plants. To obtain expression, the
DNA sequence can be altered and operably linked to other
regulatory sequences. The final product, which contains the
regulatory sequences and the therapeutic protein, is referred
to as a vector. This vector can be introduced into eukaryotic,
bacteria, insect, and/or plant cells. Once inside the cell the
vector allows the protein to be produced.
A fusion antigen comprising a protein, such as F.VIII or
FIX (or variants, polymorphisms, mutants, or fragments
thereof) linked to other amino acid sequences that do not
inhibit the desired activity of the protein, for example the
ability to increase hemostasis. In one embodiment, the other
amino acid sequences are no more than 10, 20, 30, or 50
amino acid residues in length.
One of ordinary skill in the art will appreciate that the
DNA can be altered in numerous ways without affecting the
biological activity of the encoded protein. For example, PCR
can be used to produce variations in the DNA sequence
which encodes an antigen. Such variants can be variants
optimized for codon preference in a host cell used to express
the protein, or other sequence changes that facilitate expres
S1O.
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therapeutically effective amount of F.VIII is at least 5 mg of
clotting factor per 1 kg of Subject daily and a therapeutically
effective amount of F.IX is at least 50 mg of clotting factor
per 1 kg of Subject daily.
5 In a particular embodiment, oral administration is
achieved by feeding the subject a therapeutically effective
amount of the clotting factor. For example, the clotting
factor can be a recombinant clotting factor present in milk of
a transgenic mammal, which is fed to a hemophiliac. In one
10 embodiment, the clotting factor. Such as F.IX, is present in
milk obtained from a transgenic pig expressing the clotting
factor, such as recombinant F.IX. The clotting factors can be
present in at least one pharmaceutically effective carrier,
15

Such as water or milk.
The methods disclosed herein can further include admin

istering to a Subject an isolated recombinant nucleic acid
molecule encoding a clotting factor, such that the clotting
factor is expressed in the Subject.
Also disclosed herein is a method for increasing hemo
20 Stasis in a Subject having a hemophilia, which includes, and
in some examples consists of orally administering to the
Subject a therapeutically effective amount of a clotting factor
and at least one pharmaceutically acceptable carrier which is
not a liposome. In other examples, the pharmaceutical
25 compositions disclosed herein (including clotting factors)
can be administered in combination, or separately, with one
or more other therapeutic treatments, such as other agents

Vector: A nucleic acid molecule as introduced into a host

cell, thereby producing a transformed host cell. A vector can
include nucleic acid sequences that permit it to replicate in 30
the host cell. Such as an origin of replication. A vector can
also include one or more selectable marker genes and other
genetic elements known in the art.
Additional definitions of terms commonly used in
molecular genetics can be found in Benjamin Lewin, Genes 35
Vpublished by Oxford University Press, 1994 (ISBN 0-19
854287-9); Kendrew et al (eds.), The Encyclopedia of
Molecular Biology, published by Blackwell Science Ltd.,
1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.),
Molecular Biology and Biotechnology: a Comprehensive 40
Desk Reference, published by VCH Publishers, Inc., 1995
(ISBN 1-56081-569-8).
Disclosed herein is a method for increasing hemostasis in
a subject having a hemophilia by orally administering to the
Subject a therapeutically effective amount of a clotting factor 45
not present in a liposome, Sufficient to induce oral tolerance
and Supply exogenous clotting factor to the Subject. In one
embodiment, hemophilia is a result of impaired expression
of a clotting factor. In yet another embodiment, increasing
hemostasis comprises decreasing blood clotting time. For 50
example, blood clotting time can be decreased by at least
50%, for example at least 60%, at least 70%, at least 80%,

that increase hemostasis.

A method is also disclosed for orally administering a
recombinant clotting factor to a Subject for treatment of a
hemophilia by orally administering milk containing recom
binant clotting factor to the subject at a therapeutically
effective amount Such that hemostasis in the Subject is
increased, thereby treating the hemophilia. In one embodi
ment, the milk contains at least 2 g recombinant clotting
factor/liter of milk. At this concentration, a 70 kg human
would drink about 0.175 liters of milk daily to achieve an
effective dose of about at least 5 mg/kg or about 1.75 liters
of milk to achieve an effective dose of about at least 50

mg/kg. The milk can be obtained from a transgenic mammal,
Such as a pig which expresses the clotting factor (or other
therapeutic protein) in its milk. In a particular example, the
milk can contain recombinant F.IX antigen at a concentra
tion of about 2 g per liter, for example about 2.5g per L.
either expressed in the milk or exogenously added to the
milk.

Also disclosed herein is a method for orally administering
a recombinant clotting factor to a subject for treatment of a
hemophilia by expressing the clotting factor in a mammal
such that the clotting factor is expressed in milk of the
mammal and orally administering the milk in which the
clotting factor has been expressed to the Subject at a thera
peutically effective amount such that blood clotting time in
at least 85%, at least 90%, at least 95%, at least 98%, or even
at least 99% compared to a blood clotting time of an the subject is reduced, thereby treating the hemophilia. In a
untreated hemophilic subject. The blood clotting time can be 55 particular embodiment, the hemophilia is hemophilia B and
measured using an activated partial thromboplastin time the clotting factor is F.IX.
(APTT) assay or by a bleeding time assay.
Further disclosed is a method for orally administering a
In another embodiment, the clotting factor is administered recombinant F.IX protein to a subject for treatment of
in absence of an anti-immune therapy. In a particular hemophilia B by orally administering milk containing
embodiment, a therapeutically effective amount of a clotting 60 recombinant F.IX protein at a therapeutically effective
factor is a daily dose of at least 5 mg of clotting factor per amount Such that blood clotting time in the Subject is
kg of Subject, for example at least 50 mg of clotting factor reduced, thereby treating the hemophilia B.
per kg of Subject. The clotting factor can be administered
Also disclosed is a method of orally administering to a
daily or every other day. The subject to be treated can be a hemophiliac a therapeutically effective amount of a clotting
mammal, for example a human or dog. The hemophilia can 65 factor protein sufficient to induce oral tolerance to the
be hemophilia A and the clotting factor F.VIII, or hemophilia clotting factor protein and Supply exogenous clotting factor
B and the clotting factor F.IX. In one embodiment, a protein to the hemophiliac, wherein the clotting factor
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protein is not present in a liposome, and wherein oral
tolerance prepares the hemophiliac for in Vivo expression of
a clotting factor gene. In a particular embodiment, the
clotting factor is F.VIII or FIX.
Disclosure of certain specific examples is not meant to
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EXAMPLE 2

Factor IX Oral Tolerance
5

exclude other embodiments.

described in EXAMPLE 1.

EXAMPLE 1.

Ovalbumin Oral Tolerance

This example describes the methods used to induce oral
tolerance in mice to ovalbumin (OVA) by first orally admin
istering OVA prior to immunization with OVA. Similar
methods can be used to test any antigen of interest, Such as
F.VIII, FIX, protein C, or insulin, in any animal/subject of

10

15

interest.

Normal B10 mice were fed OVA by adding the protein to
their drinking water for eight days at concentrations of 0.02,
0.2 or 2 mg/ml. The mice drank an average of 5.2 ml/mouse?
day. Therefore, the doses were 0.1, 1.0 and 10 mg/mouse/
day of OVA. Control mice only drank water. Two days after
the last feeding, all mice were immunized with 50 ug OVA
in complete Freund's adjuvant (CFA) (Sigma, St. Louis,
Mo.) in the left footpad. Seven days later, footpad swelling
was determined by measuring the thickness of the footpad.
Measurement of the right (un-injected) footpad served as an
untreated control. The footpad swelling responses were
compared between injected, OVA-fed mice and injected,
non-OVA fed control mice. As shown in FIG. 1A, the
footpads of OVA-fed mice swelled less than those of the
unfed group.
To compare the amount of IL4, TGF-B, and IFN-Y pro
duction, mice were fed 0.1 mg OVA for 10 days, then
immunized as described above. Seven days after immuni
Zation, lymph nodes draining the immunization site were
harvested and cultured in vitro with 100 ug/ml OVA. The
culture was carried in 96 well round bottom plates, with
500,000 cells per well, for four days. For the last 8 hours of
the culture, cells were pulsed with tritiated thymidine to
assay for proliferation using a beta plate cell harvester. For
IL-4 and IFN-y, supernatants were assayed at day four. For
TGF-B, after four days in culture, cells were washed,

Briefly, normal B10. A mice (F.IX-/+) or hemophilia B
mice (F.IX-/-) were fed transgenic human F.IX (hFIX) in
pig milk (see EXAMPLE 5) or control pig milk (no hF.IX)
every other day for three weeks. Individual mice drank about
4 ml (10 ugh F.IX/day/mouse) of the milk at each time. Two
days after the last feeding, all mice were immunized with 50
ug human F.IX emulsified in CFA at the base of the tail.
Eight days later, the amount of T cell proliferation was
determined by culturing T-cells from the lymph nodes with
graded concentrations of human F.IX (purified from the
transgenic pig milk) for four days using the methods
described in EXAMPLE 1. As shown in FIGS. 2A and 2B,

feeding mice human F.IX had a similar effect to the result
observed in EXAMPLE 1 for OVA, in that it decreased T

cell proliferation upon Subsequent immunization with
25

human F.IX in CFA.
To demonstrate that oral administration of F.IX induces

30

local immunity, hemophiliac B mice were fed transgenic
FIX in milk (see EXAMPLE 5) while normal mice did not
receive F.IX, as described above. Subsequently the level of
intestinal IgA to FIX was measured by collecting stool
samples, dissolving them in PBS, and assaying for IgA using
standard ELISA methods. As shown in FIG. 2C, feeding
FIX induces local immunity as measured by the production
of secretory IgA.

35

EXAMPLE 3

Antibodies Produced by Orally Tolerized
Hemophilia B Mice Do Not Result in Clinical
40

Resistance to Infused FIX

45

To measure IgG1 and IgG2a antibodies specific for hF.IX,
plates were coated with hE.IX (10 g/ml in PBS) then
blocked with BSA overnight. After five washes, serum
samples from the normal and hemophilia B mice fed as

50

hours. The plates were then washed and Subsequently incu
bated with HRP-conjugated goat-anti-mouse IgG1 and
IgG2a for two hours, followed by TMP for color develop
ment, and plates Subsequently read on an ELISA plate

described in EXAMPLE 2 were added and incubated for two

restimulated with APC and OVA in serum-free medium, and

Supernatants assayed at day three. ELISA assays were per
formed using commercially available kits from Endogen
(Rockford, Ill.), according to the manufacturers instruc
tions. As shown in FIG. 1B, OVA-fed mice made high levels
of IL-4 and TGF-B, but low levels of IFN-Y compared to
mice in the unfed group.
To compare the amount of T-cell proliferation, mice were
fed doses of OVA ranging from 0.001-10 mg every-other
day for five feeds and immunized with 50 ug OVA in CFA.
Seven days after immunization, lymph nodes draining the
immunization site were harvested by Surgical dissection.
CD4 T-cells were purified from the lymph nodes and cul
tured in vitro with irradiated spleen cells and a graded

This example describes experiments in which mice devel
oped oral tolerance to FIX by orally administering F.IX
prior to immunization with F.IX, using the methods

reader. As shown in FIGS. 3A and 3B, whereas unfed control

mice made strong IgG2a antibodies, mice fed with hF.IX
made no detectable IgG2a, but did produce IgG1.
Therefore, in normal mice, oral administration of human
55

F.IX did not completely inhibit the production of small

60

detected in ELISA assays, although it caused a shift from
IgG2a to IgG1 (FIGS. 3A and 3B). However, CFA is the
strongest adjuvant known, and may elicit antibody produc
tion that would not occur under conditions that more closely

amounts of antibodies after immunization in CFA, as

concentration of OVA as described above. As shown in FIG.

resemble a clinical situation. However, antibodies detectable

1C, T cells in the draining lymph nodes of OVA-fed mice
proliferated less than those mice in the unfed group. Since
T cells in lymph nodes proliferate in response to regional
antigenic stimulation, the reduction in T cell proliferation
was a measure of decreased antigenic stimulation from OVA
injection in the footpad.

in ELISA assays may bind to denatured proteins, but may
not act as inhibitors of the native protein. Therefore, whether
orally tolerized hemophiliac mice would made antibodies
65

after CFA immunization, and whether these antibodies
would act as inhibitors and lead to resistance to treatment,
was determined.

US 7,220,718 B2
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Hemophilia B mice were fed transgenic F.IX milk, or fed
milk without FIX, every other day for two weeks. Two days
after the last feeding, mice were immunized with h.FIX in
CFA as described above. Nine days later, the tail vein was
infused with a dose of F.IX just over the borderline for
correcting the bleeding time (0.13 IU of functional hF.IX
purified from the pig milk). This amount was chosen
because it is in the range of F.IX most sensitive to inhibitors.

18
As shown in FIGS. 5A-5C, oral tolerance occurred in

sheep. PBMCs from lambs that drank their mother's milk
(sheep milk) did not proliferate in vitro to a sheep milk
protein, casein, upon immunization as young adults (FIG.
5A). In contrast, lambs that were fostered on cow's milk
showed a vigorous proliferative response (FIG. 5B). In
addition, orally tolerized lambs failed to make antibodies to
casein (FIG.5C).

Bleed times were measured six hours later. As shown in FIG.

4, group 2 shows that this dose of hF.IX partially corrected
the bleeding time (clotting occurred within 7-10 minutes).
This clotting time is about twice as long as the 4-6 minutes
clotting time of normal mice (see FIG. 7A), showing that
0.13 IU of functional hFIX is a highly sensitive range of
factor. Bleeding times in the immunized unfed F.IX hemo
philia B mice (FIG. 4, group 3) were as long as those in mice
not given factor (FIG. 4, group 1), showing that the anti
bodies elicited by a single immunization with hFIX in CFA
were highly inhibitory. However, the F.IX knock-out mice
(hemophilia B mice) that were orally tolerized before immu
nization (FIG. 4, group 4) showed little evidence of inhibi
tors, as their bleeding times were only slightly longer than

10

Orally Administered Clotting Factors Remain
Functional
15

those of infused mice that had not been immunized.

These results demonstrate that although orally tolerized
mice produce antibodies when immunized with a very
strong adjuvant, these antibodies do not lead to clinical
resistance to hE.IX infusion. Therefore, the antibodies may
be specific for denatured forms of the factor that occur in the
adjuvant mixture and on ELISA plates, but the antibodies are
not inhibitory to the native form of hF.IX in vivo.
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methods described in EXAMPLES 1 and 2. Similar methods

COunter.

To measure casein-specific IgG in serum, maleic anhy
dride activated polystyrene plates were coated with sheep
casein (10 ug/ml) for 30 minutes at 37° C. and blocked with
PBS 1% BSA (bovine serum albumin) for 30 minutes. After
discarding the blocking buffer and five washes, serum
samples (/10 diluted) were added into the wells and incu
bated for two hours. The plates were subsequently washed,
and horseradish peroxidase (HRP) conjugated rabbit anti
sheep IgG (clone N126E, Southern Biotechnology Associ
ates) was added and incubated for two hours, followed by
TMP for color development, and plates subsequently read on
an ELISA plate reader.

60) or water alone. One hour after feeding, plasma was
obtained from the mice and added to sheep T cells that are
reactive against human F.IX, to determine if the plasma
could stimulate the sheep PBMCs. Sheep T cells reactive
against human F.IX were generated by immunizing sheep
with human F.IX (100 ug) in CFA. PBMC from these sheep
proliferate in a dose-dependent manner to purified human
F.IX in vitro (FIG. 4A, dotted line) and therefore can be used
to measure the amounts of human F.IX in blood samples.
The plasma was diluted from about 1:10 and decrease in

10-fold dilutions down to 1:107. Cells were cultured for four

40

CFA. Three and six weeks later, lambs were boosted with 0.5

mg casein in incomplete Freund's adjuvant (IFA) (Sigma).
Two months after the last immunization, peripheral blood
mononuclear cells (PBMCs) were assayed for proliferation
in the presence of titrated doses of sheep casein. Sheep
PBMCs were isolated by centrifugating the blood through a
lymphoprep gradient. Cells layered on the lymphoprep were
collected and cultured in vitro in 96 well plates for four days
in the presence of casein. Proliferation was measured by
pulsing the cells with tritiated thymidine during the last eight
hours of the culture and reading the results on a beta plate

Factor IX
Normal B10. A mice were fed either 0.5 ml of human F.IX

human F.IX; see Van Cott et al. 1999. Genet. Anal. 15:155

This example describes the methods used to determine if
sheep would develop oral tolerance to casein using the
can be used to test any antigen of interest, such as F.VIII,
F.IX, protein C, or insulin, in any animal/subject of interest.
Lambs were raised on sheep or cow milk. After 3-4
months, lambs were immunized with 0.5 mg sheep casein in

Having demonstrated that oral tolerance to several differ
ent antigens can be achieved, it was then demonstrated that
the antigen remained functional after passing through the
digestive system into the bloodstream. This example
describes methods that were used to test the functionality of
F.VIII and F.IX after they were orally administered. Similar
methods can be used to identify a therapeutically effective
amount of clotting factor necessary to increase hemostasis in
a Subject, Such as in a hemophiliac.
in transgenic pig milk (which contained about 2.5 g/L of

EXAMPLE 4

Casein Oral Tolerance

EXAMPLE 5

45

days in 96 well plates and pulsed with tritiated thymidine the
last eight hours of the culture. As a control, sheep T cells
were cultured in the presence of purified human F.IX.
As shown in FIG. 6A, FIX present in the pig milk passed
into the plasma after feeding. Sheep PBMC responded
strongly to the fed mouse plasma (FIG. 6A, solid line), but
not to plasma from unfed mice (FIG. 6A, bottom dashed
line). It was determined that the fed mouse plasma contained
about 6.7 ug/ml of human F.IX, indicating that about 0.1%
of the fed F.IX entered the circulation. This result was

55

confirmed by a sandwich ELISA to detect human F.IX in
plasma after feeding (FIG. 6B). For the ELISA assay, 96
well flat-bottom ELISA plates from PIERCE (Rockford, Ill.)
were coated with sheep-anti-human F.IX polyclonal anti
body (Cedarlane Laboratories, Ontario, Canada), then
blocked with 10% BSA. Mouse plasma were diluted from

60

hours, washed with wash buffer, and then HRP-conjugated
polyclonal goat anti-human F.IX antibodies (Cedarlane
Laboratories) added for two hours. Color was developed by
adding TMP, and results obtained using an ELISA plate

50

/10 to /10,000 and added into the wells, incubated for two

reader. As shown in FIG. 6B, the amount of F.IX in the blood

of F.IX-fed mice was similar when measured by ELISA to
that measured by the PBMC (FIG. 6A) and that most F.IX
passes into the circulation as intact protein.
65

To determine if fed human F.IX retains its native form and

functional ability to treat bleeding episodes, F.IX-containing
transgenic pig milk (1.25 mg FIX) was fed to hemophilia B
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mice (a F.IX knock-out obtained from Dr. Katherine High, an additional 7 days. Mice were then boosted with hF.VIII
Children’s Hospital of Philadelphia; approximately 20 g in in IFA, and again assayed for bleeding time 7 days later.
weight) over a period of two months every other day and the Even after this second immunization with a strong adjuvant,
effect on a bleeding defect determined. Bleeding time was the previously orally tolerized mice exhibited normal bleed
measured by cutting the tip of the tail and waiting for it to 5 ing times, while the un-tolerized controls did not.
The mice were then sacrificed and checked for antibodies
clot. Normal mice clot in about four minutes (FIG. 7A, open
squares). In contrast, hemophilia B mice do not stop bleed to F.VIII. Control mice had high levels of IgG2a antibodies
ing (FIG. 7A, open circles) and the tail tip is cauterized to (FIG. 8D, open circles), which is consistent with their
stop bleeding after fifteen minutes. As shown in FIG. 7A, inability to respond to treatment with hE.VIII. In contrast,
oral administration of F.IX immediately corrected the bleed 10 the orally tolerized mice had barely detectable levels of
ing defect (FIG. 7A, closed circles). In addition, this result IgG2a (FIG. 8D, closed circles). Although orally tolerized
is sustained for a period of at least two months (FIG. 7B). mice did have some IgG1 antibodies specific for hE.VIII,
indicating that anti-FIX antibodies are not being generated, after immunization (FIG. 8C), these antibodies behaved like
which allows the F.IX to remain functional. Therefore, oral
the similar antibodies in orally tolerized wild type mice.
administration of human F.IX is an effective treatment for 15 These antibodies are not inhibitors, as they did not affect the
bleeding, and does not induce inhibitory immunity, even bleeding time (FIG. 8C).
following a long-term treatment.
This is the first demonstration that missing clotting factors
can
be demonstrated in the circulation of hemophiliac mice
Factor VIII
as early as 45 minutes after feeding, and that the orally-fed
To demonstrate that hemophilia A, caused by the lack of 2O clotting factors are functional, as demonstrated by correction
functional F.VIII, could also be treated by oral administra in bleeding time. Although it is commonly assumed that
tion of factor, milk from a transgenic pig engineered to dietary proteins are digested completely to free amino acids
secrete hE.VIII was fed to F.VIII knock-out mice. However,
within the lumen of the gastrointestinal tract and that only
this treatment had no effect on oral tolerance or on clotting trace amounts of macromolecular fragments enter the cir
times. It was possible that the dose of F.VIII was too low, 25 culation having no clinical relevance, there is mounting
since this particular transgenic strain of pig does not produce evidence that suggests the opposite. The most compelling
large quantities of F.VIII (Paleyanda et al. Nature Biotech.
showing that intact proteins or macromolecular
15:971-5, 1997). Another explanation is that hF.VIII is evidence
fragments are absorbed is provided by the demonstration of
almost 8 times larger than F.IX, with a molecular weight of antibodies to many food proteins that occur in the circulation
nearly 240,000 kDa, which might make it difficult to pass 30 of healthy individuals and experimental animals. For
into the bloodstream.
example, 5% of recombinant human erythropoietin (about
To distinguish between these possibilities, the studies 40 kDa) fed to 10-day old rats was demonstrated in the
were repeated with commercially available F.VIII (Baxter) serum as early as one hour after feeding (Miller-Gilbert et al.
purified from human plasma (Red Cross Holland labs, 2001. Pediatr. Res. 50:261-7). Serum erythropoietin levels
Rockville, Md.). hF.VIII (100 g) was added to 0.5 ml of is remained steady for up to 6 hours as opposed to the rapid
water or cow's milk and fed to hemophilia A mice by peak and fall observed after intravenous administration.
gavage. Bleeding time was assayed 45 minutes later. As Although orally administered erythropoietin showed func
shown in FIG. 8A, the bleeding time was corrected in tional activity in Hess mice by stimulation erythropoiesis,
hemophilia A mice fed hE.VIII either in water or milk. this could have been due to the stimulation of erythropoietin
Therefore, sufficient hF.VIII passes into the bloodstream in 40 receptors on the enterocytes within the gastrointestinal tract.
native form to function as a clotting factor, despite the size
Similarly, gastrointestinal absorption of intact TGFB1 was
and complexity of the molecule.
demonstrated after administration (by gavage) of radiola
To determine whether hE.VIII might be passing through beled TGFB into the stomachs of 5-day old pups (Letterio et
Small lacerations created by the gavage process, F.VIII was al. 1994. Science 264:1936-8). Although the neonatal gut is
fed to the mice in a more physiologic way, by dissolving 400 45 very permeable to intact proteins, similar results were
ugh F.VIII in 8 ml of commercial half cream/half milk and observed in adult animals. In mice, rats, and fish fed
offering this to the mice in petri dishes. Three mice drank ovalbumin, casein or HRP respectively, between 0.005 to
about 12 ml of this mixture in about 2 hours, delivering 0.7% of the total fed amount was measured in the circulation
about 200 ug to each mouse daily. Bleeding time was either by ELISA or Western analysis (Gonnella et al. 2001.
assayed 45 minutes later. As shown in FIG. 8B, this method 50 J. Immunol. 166:4456-64). Interestingly, the amount of
was also an effective method to treat the bleeding disorder. antigen that passed into the circulation was much higher in
To demonstrate that feeding hF.VIII induces oral toler B-cell deficient mice compared to wild type controls, Sug
ance, hF.VIII was fed to hemophilia A mice (F.VIII knock gesting that the lack of M cells does not affect the transport
out mice) in commercial half and half (600 ug F.VIII/12 ml of proteins across the gut.
of half and half) daily for eight days. Control mice were fed 55 Although both intravenous and oral administration of
plain half and half. On day 10, mice were bled to determine proteins results in detectable serum levels, antigen entry
the bleeding time (FIG. 8C, pre-imm), then immunized with through the mucosa provides certain benefits. First, phar
hF.VIII in CFA as described in the Examples above. Seven macokinetically, as opposed to a rapid rise and decline as
days later, all mice were fed hF.V111-containing half-and seen after intravenous administration, oral administration
half to determime if immunization-induced inhibitors would 60 provides relatively steady levels of the protein. Second,
prevent the oral dose of F.VIII from functioning as a clotting immunologically, it generates a gut-oriented immunity,
factor.
which avoids inhibitory or rejecting antibodies. Therefore,
A single immunization did not inhibit the function of the feeding F.VIII and FIX in hemophilia A and B, respectively,
orally administered factor in previously orally tolerized mice is a simple, noninvasive and effective method of treating
(FIG. 8C, closed circles), but did cause a loss of function in hemophilia. In addition, it induces oral tolerance, avoiding
previously unfed controls (FIG. 8C, open circles). The test the generation of inhibitory antibodies and a vigorous T-cell
group was fed every other day, starting again from day 19 for response against missing clotting factors.
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EXAMPLE 6

Comparison of Oral Administration of Clotting
Factors in Water and Milk

To determine if the presence of milk was critical to
achieve oral tolerance and maintain proper function of the
clotting factor, the administration of F.VIII or F.IX in milk
and water was compared.
Purified F.VIII from human serum was orally adminis
tered to hemophilia A mice (F.VIII knock out; Dr. Kang, U.
of Iowa.) in cow's milk or in water. Mice were fed 100 ug
of F.VIII (antihemophilic factor, Baxter, Deerfield, Ill.) by
gavage in 0.5 ml of water or cow's milk. Bleeding time was
measured as described above, 45 minutes after feeding. As
shown in FIG. 8A, feeding F.VIII derived from human
plasma that is added into cow's milk or water corrects
bleeding time in hemophilia A mice. Therefore, the presence
of milk when orally administering F.VIII is not critical.
To determine if the presence of milk was critical to

10

15

Zation.

Three assays can be used to detect immune responses
against F.IX. First, the amount of peripheral blood mono
nuclear cell proliferation can be determined. One week and

achieve oral tolerance to FIX, normal B10. A mice were fed

with low (10-20 ug F.IX/feed) or high (2500 ug F.IX/feed)
does of human F.IX in pig milk or as purified plasma-derived
human F.IX (Sigma) reconstituted in water (10-20 ug F.IX/
feed) every other day for a total of five feeds. Control mice
were fed no F.IX. Two days later, mice were immunized with
0.5ug human F.IX emulsified in CFA at the base of the tail.
Seven days later, the amount of T cell proliferation was
determined using the methods described in EXAMPLE 1.
As shown in FIGS. 9A and 9B, mice fed as little as 20 lug
F.IX in milk (FIG. 9A) were almost completely unrespon
sive, while T cells from mice fed with FIX in water (FIG.
9B) retained a small amount of activity (about 3% of unfed
controls). However, administration of F.IX in water or milk
resulted in better oral tolerance than no administration of
F.IX.

In summary, a dose of 100 ug F.VIII/20 g body weight
(about 5 mg/kg), orally administered every day (or every
other day), can be used to increase hemostasis, thus treating
hemophilia A. In addition, a dose of 1 mg FIX/20 g body
weight (about 50 mg/kg), orally administered every day (or
every other day), is expected to increase hemostasis thus
treating hemophilia B. However, it is possible that lower
doses can be used, or that higher doses may be required in
a particular subject, in order to obtain a successful treatment
of hemophilia.

two weeks after immunization, 10-20 ml of venous blood is
25

To identify optimal conditions to achieve low dose oral
tolerance to human F.IX delivered in transgenic pig milk, the
following methods can be used. Similar methods can be used
to determine the conditions for other antigens, including
F.VIII, insulin, and protein C, in humans.
Lambs can be used as an experimental model. Sheep are
an outbred species and, like humans (but unlike mice), their
immune system becomes functional during the last trimester
of pregnancy. They are also easier than mice to bottle-feed.
The architecture of sheep intestines during the first 24-48
hours of life is designed to collect maternal antibodies from
colostrum, with very high levels of Fc receptors that have a
half-life of about 24 hours. Therefore, feeding of F.IX milk
is started 48 hours after birth, when the gut has settled.

collected by jugular Venipuncture, the mononuclear cells
fractionated using Percoll gradients and Subsequently cul
tured in vitro in the presence of titrated amounts of F.IX, and
assay for proliferation as described in EXAMPLES 1, 2 and
4.
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EXAMPLE 7

Determination of Parameters for Low Dose Oral
Tolerance

22
Lambs are fed 0.3 mg F.IX/kg of animal/day, the amount
of protein shown to induce low dose tolerance in 20 g mice
(FIGS. 1A-1C). The effective dose range in mice is 0.001 to
0.1 mg for OVA (0.05-5 mg/kg) and 0.003 to 0.1 mg/day for
F.IX (0.15-0.5 mg/kg). Lambs are fed daily for three weeks
with sheep milk Supplemented with pig milk containing
human F.IX (see EXAMPLE 5). A parallel control group of
lambs is Supplemented with normal pig milk containing no
human F.IX. Milk is collected, frozen immediately, and
thawed just before use. Experiments with mice demonstrate
that continuous daily feeding is the most effective way of
inducing oral tolerance.
Sheep can be immunized as early as two weeks of age. At
three weeks of age, half the lambs are immunized with F.IX
in CFA after the feedings are completed and then boosted
two weeks later with F.IX in IFA. A dose of 100 ug human
FIX is Sufficient to prime young ewes for a Subsequent
proliferative and antibody response. Lambs are tested for
various types of immunity against F.IX after each immuni

50

Second, serum F.IX specific antibody titers can be deter
mined. From each blood sample collected, serum is
extracted. Dilutions of the serum are added to ELISA plates
(Pierce) coated with human F.IX (10 ug/ml). After a two
hour incubation, the plates are washed with wash buffer,
then incubated with polyclonal HRP-conjugated goat anti
human F.IX antibodies (Cedarlane Laboratories) for two
hours. For color development TMP is added and then the
plates are read in an ELISA plate reader. Antibodies of
different classes can be identified using the sandwich ELISA
method described in EXAMPLES 4 and 5.

Third, a factor IX inhibitor assay (Bethesda Assay) can be
conducted. This functional assay measures the amount of
inhibitor antibody in serum. The Bethesda assay is an in
vitro functional assay performed by mixing plasma contain
ing unknown amounts of inhibitors (test plasma) with nor
mal plasma to determine how the test plasma prolongs the
APTT of the normal plasma.
Lambs fed human F.IX should not generate a strong
specific proliferative response, and should not develop anti
bodies against F.IX. If antibodies are produced, they will be
of the secretory IgA type and will not be inhibitory against
F.IX.

55

It is possible that the determined effective dose in sheep
or other subjects (such as humans) may differ from that in
mice. If feeding 0.3 mg/kg/day F.IX does not result in oral
tolerance, experiments can be repeated using a titration of
higher and lower doses of F.IX, to determine the appropriate
dose. In addition, it can also be determined whether feeding
during the first 48 hours of life can enhance oral tolerance.

60

EXAMPLE 8

Determination of Parameters for High Dose Oral
Tolerance
65

To determine parameters that are helpful to achieve opti
mal high dose oral tolerance to human F.IX delivered in
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transgenic pig milk, the following methods can be used.
Similar methods can be used to determine the parameters for
other antigens, including F.VIII, insulin, and protein C.
Although low dose tolerance induces remarkable reduc
tions in cellular responses, it may allow for some antibody
production. Though antibodies are unlikely to result in
rejection of cells expressing a FIX transgene, they may
inhibit the secreted product. Therefore, tolerance can also be
induced by feeding high doses of F.IX. This approach has
not been feasible in the past because of the extraordinarily
high cost of purified FIX. However, induction of oral
tolerance does not require purified antigen. As experiments
in sheep illustrate (FIGS. 5A-5C), newborns become toler
ant of milk proteins even when the proteins are given as
mixtures in normal milk. The tolerizing ability of unpurified
transgenic pig milk containing 2.5 g/L F.IX (see EXAMPLE
5) in the native situation where piglets feed continuously is

5

F.IX.
10

15

tested.

Non-transgenic piglets are fostered onto transgenic moth
ers and allowed to drink ad libitum until weaned. A control

group of foster littermates is fostered onto non-transgenic
control mothers. Two days after the animals are weaned, half
of the piglets in each group are Subcutaneously immunized
with F.IX (0.1 mg) in CFA and two weeks later, boosted with
F.IX in IFA. Half of the piglets will be un-immunized as

25

controls. One and two weeks after each immunization vari
above in EXAMPLE 7.
30
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EXAMPLE 9

Oral Tolerance in Hemophiliac Puppies
This example describes procedures that can be used to
develop oral tolerance to clotting factors in hemophiliac
puppies. The method specifically outlines methods for test
ing tolerance to FIX in hemophiliac B puppies, but those
skilled in the art will understand from the teachings herein
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1982. Blood 60:727-30; and Giles et al. 1984. Blood 63:451

6). Hemophilia A was diagnosed in a miniature Schnauzer
dog and inbreeding and crossbreeding produced 16 hemo
philic animals. Five animals developed potent antibodies to
canine F.VIII. In each case, the antibodies recognize both
canine and human, but not porcine F.VII. Following inhibi
tor development, infusion of canine cryoprecipitate was
hemostatically ineffective and F.VIII recovery at 30 minutes
is negligible.
Two canine models of hemophilia B are available. In the
Chapel Hill dog colony, hemophilia B is due to a missense
mutation, and inhibitor formation in response to canine
plasma or gene therapy maneuvers is relatively uncommon
(Evans et al. 1989. Proc. Natl. Acad. Sci. USA. 86:10095
9). However, for the Auburn dog colony, where disease is
due to a Small deletion that results in an early stop codon
(Mauser et al. 1996. Blood. 88:3451-5), inhibitor formation

the canine model (Evans et al. 1989. Proc. Natl. Acad. Sci.
USA. 86:10095-9). The course of the disease is followed,
periodically assaying for inhibitory antibodies using the
Bethesda assay (see EXAMPLE 7), especially after FIX
infusions due to bleeding episodes.
PBMC proliferation and serum antibody titers against
F.IX are also compared between control and experimental
animals, as described in EXAMPLE 4, except that the in
vitro assays are modified to Suit canine cells. For example,
IMDM plus canine serum is a superior medium for canine
proliferation assays whereas RPM plus fetal calf serum
serves well for sheep.
It is expected that the intact antigen will gain access to the
bloodstream after feeding, as was obtained for F.IX in mice
(EXAMPLE 5). To test for F.IX in plasma samples from
F.IX-fed hemophilia B and normal puppies, methods
described in EXAMPLE 5 are used.

that similar methods can be used to test for tolerance to

F.VIII in hemophiliac A puppies, or for tolerance to any
antigen in any subject having an antigen-deficiency disease.
A canine model of hemophilia A is available (Giles et al.

To assess the effect of oral tolerance on the development
of clotting factor inhibitors after immunization, canine mod
els for hemophilia are used. F.IX is administered orally to
normal puppies and to puppies with hemophilia B (Auburn
dog colony) and their spontaneous immune responses
against F.IX analyzed.
The optimal feeding dose of F.IX found to prevent devel
opment of inhibitory antibodies is used (see EXAMPLES
5-8). Normal and hemophilia B puppies are divided into two
groups: one group is fed F.IX-containing transgenic pig
milk, and the other group fed non-transgenic pig milk to
serve as controls. Puppies are fed for six weeks until they are
fully weaned.
The puppies are then infused with 50 IU/kg human F.IX
intravenously daily for two weeks, starting two days after
weaning, or earlier if necessary to control bleeding. The
generation of inhibitor antibodies after repeated intravenous
administration of human F.IX has been well established in

ous classes of immunity will be determined as described
Piglets that drank F.IX containing milk from transgenic
mothers are expected to be tolerant to FIX. This tolerance is
tested by Subsequently immunizing these piglets to human
FIX in CFA as described in the examples above. Tolerance
is achieved if there is decreased antibody formation and T
cell proliferation in these piglets compared to piglets fos
tered onto a non-transgenic mother using the methods
described in the examples above.

24
is more frequent. In both types of mutations, inhibitors to
canine F.IX can be induced by various means including
repeated injection of purified canine F.IX, or injection of
vector expressing canine F.IX. The rise in inhibitor antibod
ies correlates with fall of plasma F.IX levels (Herzog et al.
1999. Nat. Med. 5:56-63). Both colonies of dogs readily
form inhibitory antibodies following infusion of human
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To determine if the F.IX antigen remains functional after
oral administration, a functional assay is performed. For
example, an APTT assay which measures the intrinsic
coagulation activity of the plasma can be used.
Therefore, in addition to orally tolerizing the immune
system, it is determined whether Small amounts of func
tional F.IX can reach the blood and help prevent bleeding
episodes, thus increasing hemostasis.
It is expected that oral administration of F.IX by feeding
will induce oral tolerance and prevent the development of
inhibitory antibodies, as well as remain functional in the
blood, and therefore increase hemostasis and serve as a

treatment for hemophilia.
EXAMPLE 10
60

Oral Administration Followed by In Vivo Gene
Expression
65

To demonstrate that administration and Subsequent
expression of a FIX-containing transgene can be used to
treat hemophilia, adeno-associated vectors containing a FIX
gene can be used.

US 7,220,718 B2
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After orally tolerizing puppies to FIX as described in
EXAMPLE 9, adeno-associated viral vectors are used to

26
formation of antibodies against F.IX and PBMC prolifera
tion are monitored as described above.

introduce the human F.IX gene into hemophiliac puppies
In addition, hemostasis is monitored, using an APTT
orally tolerized to human F.IX to increase hemostasis. Simi assay described in EXAMPLE 7 or a bleeding time assay.
lar methods can be used in human hemophiliacs.
5 Treatment is successful if hemostasis is increased relative to
Methods for generating an introducing transgenes into a hemostasis prior to oral administration of the clotting factor,
subject are well known in the art. In addition, viral vectors or relative to untreated hemophiliacs.
for introducing a clotting factor into a subject are known.
EXAMPLE 12
Examples of methods and vectors that can be used to
introduce a clotting factor into a subject, include, but are not 10
Oral Tolerance Followed by In Vivo Gene
limited to those disclosed in: Stein et al., 2001. Mol. Ther:
Expression
3:850-6: Miller et al., 2001. N. Engl. J. Med. 344:1782-4:
Emilien et al., 2000. Clin. Lab. Haematol. 22:313-23:
As an alternative to continually orally administering a
Andrews et al., 2001. Mol. Ther. 3:329-36; Fabb et al., 2000.
Curr. Opin. Mol Ther. 2:601-6; and Lillicrap, 2000. Hae- 15 clotting factor to a Subject to increase hemostasis, once oral
matologica 85 (10 Suppl): 108-12, as well as other docu tolerance is achieved, long term treatment of the clotting
disorder can be achieved by expressing the deficient clotting
ments cited herein.
Following administration of the vector, F.IX levels in factor in vivo. Similar methods can be used to treat any
serum, as well as immunity to FIX, are monitored as antigen-deficiency disease.
described in EXAMPLES 5 and 7, over a period of one year 20 The present disclosure provides methods of expressing a
protein in a cell or tissue in vivo. In one embodiment,
or until the factor disappears, whichever comes first.
transfection of the cell or tissue occurs in vitro. In this
It is expected that oral administration of a clotting factor
the cell or tissue (Such as a graft) is removed from
by feeding will induce oral tolerance and prevent the devel example,
a
Subject
then transfected with an expression vector
opment of inhibitory antibodies, such that when the factor is 25 containingand
a cDNA encoding the protein of interest. The
Subsequently expressed recombinantly in the Subject, the
recombinant protein will not be inactivated by anti-clotting transfected cells will produce functional protein and can be
into the subject. In another embodiment, a
factor antibodies. This will result in functional clotting reintroduced
nucleic
acid
encoding
the protein of interest is administered
factor in the blood, and therefore increase hemostasis and
to a Subject directly, and transfection occurs in vivo.
serve as a treatment for hemophilia.
30
The methods disclosed herein can be used to treating a
Subject with an antigen-deficiency disease such as a subject
EXAMPLE 11
having hemophilia A or B. Such a method would increase
hemostasis (decrease blood clotting time) in hemophiliacs or
Oral Tolerance and Treatment in Humans
Subjects having other defects in blood clotting.
scientific and medical procedures required for human
This example describes methods that can be used to 35 cellThe
transfection
routine. The public availability of
induce tolerance to FIX in a human hemophiliac. Similar numerous proteinareandnowcDNA
sequences allows the devel
methods can be used to induce oral tolerance to any antigen opment of human (and other mammals)
in vivo gene expres
of interest in a human subject, for example F.VIII, insulin sion based upon these procedures. Immunotherapy
of mela
and protein C.
40 noma patients using genetically engineered tumor
Among hemophilia patients that form inhibitors, the inci infiltrating lymphocytes (TILs) has been reported by
dence of patients with large deletions is known (deletion/ Rosenberg et al. (N. Engl. J. Med. 323:570-8, 1990). In that
total inhibitor production=0.5). However, due to the cost of study, a retrovirus vector was used to introduce a gene for
widespread genetic screening, and the lack of practical neomycin resistance into TILS. A similar approach may be
consequence to the management of hemophilia patients, the 45 used to introduce a clotting factor cDNA into hemophiliacs.
incidence of inhibitor producers among those with large
In some embodiments, a method of treating Subjects
deletions is not known (inhibitor production/large dele which
under express a functional protein, or in which greater
tions).
functional protein expression is desired, is disclosed. These
The patient group most likely to benefit from treatment methods can be accomplished by introducing a gene coding
are children that have no F.IX, thus making them particularly 50 for the desired protein into a Subject. A general strategy for
prone to making inhibitors. After determining the F.IX levels transferring genes into donor cells is disclosed in U.S. Pat.
in plasma of a hemophiliac child, patients having undetect No. 5,529.774, incorporated by reference. Generally, a gene
able levels are further tested to determine whether they have encoding a protein having therapeutically desired effects is
a large F.IX deletion. From this study, the incidence of cloned into a viral expression vector, and that vector is then
inhibitor producers among those who have large deletions 55 introduced into the target organism. The virus infects the
can be determined.
cells, and produces the protein sequence in vivo, where it has
From studies on hemophiliac puppies, patients with large its desired therapeutic effect. Zabner et al. (Cell 75:207-16,
deletions are believed to be particularly prone to making
1993).
inhibitors and thus particularly at risk of becoming refrac
It may only be necessary to introduce the genetic or
tory to replacement therapy.
60 protein elements into certain cells or tissues. However, in
Hemophiliac children are orally tolerized by oral admin Some instances, it may be more therapeutically effective and
istration (feeding) of F.IX-containing transgenic milk. Alter simple to treat all of a subjects cells, or more broadly
natively, purified F.IX can be administered orally in any disseminate the vector, for example by intravascular (i.v.)
administration.
medium suitable for oral administration, including water.
The immune response to F.IX during the course of the 65 The nucleic acid sequence encoding at least one thera
disease is monitored as described in EXAMPLE 7. In
peutic agent, such as a clotting factor, is under the control of
a suitable promoter. Suitable promoters which may be
addition, the amount of functional F.IX in the blood, the
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employed include, but are not limited to, the gene’s native
promoter, retroviral LTR promoter, or adenoviral promoters,
such as the adenoviral major late promoter; the CMV
promoter; the RSV promoter; inducible promoters, such as
the MMTV promoter; the metallothionein promoter; heat
shock promoters; the albumin promoter, the histone pro
moter; the O-actin promoter, TK promoters: B19 parvovirus
promoters; and the ApoAI promoter. However the scope of
the disclosure is not limited to specific foreign genes or
promoters.

28
EXAMPLE 1.4

Production of Sequence Variants
5

10

The recombinant nucleic acid can be administered to the

subject by any method which allows the recombinant
nucleic acid to reach the appropriate cells. These methods
include injection, infusion, deposition, implantation, or topi
cal administration. Injections can be intradermal or Subcu

15

taneous. The recombinant nucleic acid can be delivered as

part of a viral vector, Such as avipox viruses, recombinant
vaccinia virus, replication-deficient adenovirus strains or
poliovirus, or as a non-infectious form Such as naked DNA
or liposome encapsulated DNA, as further described in

This disclosure facilitates the use of DNA molecules, and

EXAMPLE 13.
EXAMPLE 13

Viral Vectors for In Vivo Gene Expression
Adenoviral vectors include essentially the complete aden
oviral genome (Shenk et al., Curr: Top. Microbiol. Immunol.
1 11:1-39, 1984). Alternatively, the adenoviral vector is a
modified adenoviral vector in which at least a portion of the
adenoviral genome has been deleted. In one embodiment,
the vector includes an adenoviral 5.' ITR, an adenoviral 3'
ITR, an adenoviral encapsidation signal; a DNA sequence
encoding a therapeutic agent; and a promoter for expressing
the DNA sequence encoding a therapeutic agent. The vector
is free of at least the majority of adenoviral E1 and E3 DNA
sequences, but is not necessarily free of all of the E2 and E4
DNA sequences, and DNA sequences encoding adenoviral
proteins transcribed by the adenoviral major late promoter.
In another embodiment, the vector is an adeno-associated

virus (AAV) such as described in U.S. Pat. No. 4,797,368
(Carter et al.) and in McLaughlin et al. (J. Virol. 62:1963-73,
1988) and AAV type 4 (Chiorini et al. J. Virol. 71:6823-33,
1997) and AAV type 5 (Chiorini et al. J. Virol. 73:1309-19,
1999)
Such a vector can be constructed according to standard
techniques, using a shuttle plasmid which contains, begin
ning at the 5' end, an adenoviral 5' ITR, an adenoviral
encapsidation signal, and an E1a enhancer sequence; a
promoter (which may be an adenoviral promoter or a foreign
promoter); a tripartite leader sequence, a multiple cloning
site (which may be as herein described); a polyA signal; and
a DNA segment which corresponds to a segment of the
adenoviral genome. The DNA segment serves as a substrate
for homologous recombination with a modified or mutated
adenovirus, and may encompass, for example, a segment of
the adenovirus 5' genome no longer than from base 3329 to
base 6246. The plasmid can also include a selectable marker
and an origin of replication. The origin of replication may be
a bacterial origin of replication. A desired DNA sequence
encoding a therapeutic agent can be inserted into the mul
tiple cloning site of the plasmid.
Examples of vectors which can be used to practice the
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High et al.

thereby proteins, derived from a native protein but which
vary in their precise nucleotide or amino acid sequence from
the native sequence. Such variants can be obtained through
standard molecular biology laboratory techniques and the
sequence information disclosed herein.
DNA molecules and nucleotide sequences derived from a
native DNA molecule can also be defined as DNA sequences
which hybridize under stringent conditions to the DNA
sequences disclosed, or fragments thereof. Hybridization
conditions resulting in particular degrees of stringency vary
depending upon the nature of the hybridization method and
the composition and length of the hybridizing DNA used.
Generally, the temperature of hybridization and the ionic
strength (especially the Na" concentration) of the hybrid
ization buffer determines hybridization stringency. Calcula
tions regarding hybridization conditions required for attain
ing particular amounts of stringency are discussed by
Sambrook et al. (Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor, N.Y., 1989, Chapters 9 and 11), herein
incorporated by reference. Hybridization with a target probe

labeled with “P-dCTP is generally carried out in a solution

of high ionic strength such as 6xSSC at a temperature that
is about 5-25° C. below the melting temperature, T. An
example of stringent conditions is a salt concentration of at
least about 0.01 to 1.0 M Na ion concentration (or other
salts) at pH 7.0 to 8.3 and a temperature of at least about 30°
C. for short probes (e.g. 10 to 50 nucleotides). Stringent
conditions can also be achieved with the addition of desta

50
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methods disclosed herein include those disclosed in: WO

95/27512 to Woo et al., WO 127303 to Walsh et al.: U.S. Pat.
No. 6,221,349 to Couto et al., U.S. Pat. No. 6,093,392 to

Disclosed herein methods for treating antigen-deficiency
diseases by oral administration of the appropriate antigen or
protein. It is understood by those skilled in the art that use
of non-native antigen sequences (such as polymorphisms,
fragments, or variants) can be used to practice the methods
of the present disclosure, as long as the distinctive functional
characteristics of the antigen are retained. For example, F.IX
or F.VIII variants can be used to practice the methods
disclosed herein if they retain their ability to increase
hemostasis. This activity can readily be determined using the
assays disclosed herein, for example those described in
EXAMPLES 5 and 9. In yet other embodiments, F.IX or
F.VIII has the distinct characteristic of being reduced in
patients Suffering from hemophilia.

65

bilizing agents such as formamide. For example, conditions
of 5xSSPE (750 mM NaCl, 50 mM. Na phosphate, 5 mM
EDTA, pH 7.4) at 25-30° C. are suitable for allele-specific
probe hybridizations.
The degeneracy of the genetic code further widens the
Scope of the present disclosure as it enables major variations
in the nucleotide sequence of a DNA molecule while main
taining the amino acid sequence of the encoded protein. For
example, the amino acid Ala is encoded by the nucleotide
codon triplet GCT, GCG, GCC and GCA. Thus, the nucle
otide sequence could be changed without affecting the
amino acid composition of the encoded protein or the
characteristics of the protein. Based upon the degeneracy of
the genetic code, variant DNA molecules may be derived
from a cDNA molecule using standard DNA mutagenesis
techniques as described above, or by synthesis of DNA
sequences. DNA sequences which do not hybridize under
stringent conditions to the cDNA sequences disclosed by
virtue of sequence variation based on the degeneracy of the
genetic code are also comprehended by this disclosure.
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Clotting factor variants, fragments, fusions, and polymor
phisms will retain the ability to increase hemostasis, as
determined using the assays disclosed herein, for example
by performing an APTT assay (EXAMPLE 9) or a bleeding
time assay. Variants and fragments of a protein may retain at
least 70%, 80%, 85%, 90%, 95%, 98%, or greater sequence
identity to a protein amino acid sequence and maintain the
functional activity of the protein as understood by those in
skilled in the art. Examples of clotting factor variants,
include, but are not limited to those disclosed in U.S. Pat.
No. 6,221,349 to Couto et al., U.S. Pat. No. 4,877,614 to
Andersson et al.; EP 770396 to Zimmermann et al.; U.S. Pat.

10

No. 6,093,392 to High et al.; and EP 0294.910 to van Ooyen
et al.
15

EXAMPLE 1.5

Recombinant Expression of Proteins
With publicly available cDNA and corresponding amino
acid sequences, as well as the disclosure herein of variants,
fragments and fusions thereof, the expression and purifica
tion of any publicly known protein by standard laboratory
techniques is enabled. The purified protein can be used for
patient therapy. For example, mammals that produce recom
binant F.VIII or F.IX in their milk are known (see U.S. Pat.

esterS.

25

No. 5,880,327 to Lubon et al. and Van Cott et al. 1999.

Genet. Anal. 15:155-60, respectively), and can be used to
practice the methods disclosed herein. However, one skilled
in the art will understand that the orally administered
clotting factor can be produced in any cell or organism of
interest, and purified prior to administration to a subject, as
an alternative to feeding the Subject milk containing the
recombinant clotting factor.
Methods for producing recombinant proteins are well
known in the art. Therefore, the scope of this disclosure
includes recombinant expression of any antigen/protein. For
example, see U.S. Pat. No. 5,342,764 to Johnson et al.; U.S.
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O150735; U.S. Pat. No. 6,221,349 to Couto et al.; U.S. Pat.
No. 5,804,420 to Chan et al. and U.S. Pat. No. 4,770,999 to
Kaufman et al.
EXAMPLE 16
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Peptide Modifications
Orally administered proteins can be modified using a
variety of chemical techniques to produce derivatives having
essentially the same activity as the unmodified peptides, and
optionally having other desirable properties. For example,
carboxylic acid groups of the peptide, whether carboxyl
terminal or side chain, can be provided in the form of a salt
of a pharmaceutically-acceptable cation or esterified to form
a C-C ester, or converted to an amide of formula NRR
wherein R and R2 are each independently H or C-C alkyl,
or combined to form a heterocyclic ring, Such as a 5- or
6-membered ring. Amino groups of the peptide, whether
amino-terminal or side chain, can be in the form of a

pharmaceutically-acceptable acid addition salt, Such as the
HCl, HBr, acetic, benzoic, toluene sulfonic, maleic, tartaric

To maintain a functional peptide, particular peptide vari
ants will differ by only a small number of amino acids from
a peptide. Such variants can have deletions (for example of
1-3 or more amino acids), insertions (for example of 1-3 or
more residues), or substitutions that do not interfere with the
desired activity of the peptide. Substitutional variants are
those in which at least one residue in the amino acid

30

Pat. No. 5,846,819 to Pausch et al.: U.S. Pat. No. 5,876,969

to Fleer et al. and Sambrook et al. (Molecular Cloning. A
Laboratory Manual, Cold Spring Harbor, N.Y., 1989, Ch.
17, herein incorporated by reference).
In addition, methods for producing recombinant clotting
factors are known, for example as disclosed in EP 0294910
(and references therein); EP 0160457; EP 0253.455; EP

30
and other organic salts, or may be modified to C-C alkyl
or dialkyl amino or further converted to an amide.
Hydroxyl groups of the peptide side chain can be con
verted to C-C alkoxy or to a C-C ester using well
recognized techniques. Phenyl and phenolic rings of the
peptide side chain can be substituted with one or more
halogen atoms, such as F, Cl, Br or I, or with C-C alkyl,
C-C alkoxy, carboxylic acids and esters thereof, or
amides of Such carboxylic acids. Methylene groups of the
peptide side chains can be extended to homologous C-C,
alkylenes. Thiols can be protected with any one of a number
of well-recognized protecting groups, such as acetamide
groups. Those skilled in the art will also recognize methods
for introducing cyclic structures into the peptides disclosed
herein to select and provide conformational constraints to
the structure that result in enhanced stability. For example,
a carboxyl-terminal or amino-terminal cysteine residue can
be added to the peptide, so that when oxidized the peptide
will contain a disulfide bond, generating a cyclic peptide.
Other peptide cyclizing methods include the formation of
thioethers and carboxyl- and amino-terminal amides and

sequence has been removed and a different residue inserted
in its place. In particular embodiments, such variants have
amino acid substitutions of single residues, for example 1, 3,
5 or even 10 substitutions in a protein.
Peptidomimetic and organomimetic embodiments are
also disclosed herein, whereby the three-dimensional
arrangement of the chemical constituents of Such peptido
and organomimetics mimic the three-dimensional arrange
ment of the peptide backbone and component amino acid
sidechains in the peptide, resulting in Such peptido- and
organomimetics of a clotting factor having the ability to
increase hemostasis. For computer modeling applications, a
pharmacophore is an idealized, three-dimensional definition
of the structural requirements for biological activity. Pep
tido-and organomimetics can be designed to fit each phar
macophore with current computer modeling Software (using
computer assisted drug design or CADD). See Walters,
“Computer-Assisted Modeling of Drugs, in Klegerman &
Groves, eds., 1993, Pharmaceutical Biotechnology, Inter
pharm Press: Buffalo Grove, Ill., pp. 165-174 and Principles
of Pharmacology (ed. Munson, 1995), chapter 102 for a
description of techniques used in CADD.
EXAMPLE 17
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Pharmaceutical Compositions and Modes of
Administration

60
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The pharmaceutically effective carriers useful herein are
conventional. Remington's Pharmaceutical Sciences, by
Martin, Mack Publishing Co., Easton, Pa., 15th Edition
(1975), describes compositions and formulations suitable for
pharmaceutical delivery.
Oral Administration of Antigens and Proteins
In an embodiment in which an antigen, such as a clotting
factor, is administered to a Subject, the antigen is delivered
enterally, for example orally (e.g., by feeding), or rectally
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(e.g., by Suppository). The present disclosure also provides
pharmaceutical compositions which include a therapeuti
cally effective amount of a clotting factor alone or with a
pharmaceutically acceptable carrier. Furthermore, the phar
maceutical compositions or methods of treatment can be
administered in combination (or separately) with one or
more other therapeutic treatments, such as other agents that

32
particles, microcapsules, receptor-mediated endocytosis
(Wu and Wu, J. Biol. Chem. 1987, 262:4429-32), and
construction of therapeutic nucleic acids as part of a retro
viral or other vector. Methods of introduction include, but

are not limited to, intradermal, intramuscular, intraperito
neal, intravenous, Subcutaneous, intranasal, and oral routes.

increase hemotasis. Embodiments of the disclosure com

prising medicaments can be prepared with conventional
pharmaceutically acceptable carriers, adjuvants and counte

10

rions as would be known to those of skill in the art.

The antigen can be administered in combination with at
least one, for example one or more pharmaceutically effec
tive carriers, such as a pharmaceutically and physiologically
acceptable fluid. Examples of pharmaceutically effective
carriers include, but are not limited to milk, water, physi
ological saline, balanced salt solutions, aqueous dextrose,
sesame oil, glycerol, ethanol, combinations thereof, or the
like, as a vehicle. The carrier and composition can be sterile,

15

reservoir.

Liposomes fuse with the target site and deliver the con
tents of the lumen intracellularly. The liposomes are main
tained in contact with the target cells for a sufficient time for
fusion to occur, using various means to maintain contact,
Such as isolation and binding agents. Liposomes can be
prepared with purified proteins or peptides that mediate

and the formulation Suits the mode of administration. In

addition to biologically-neutral carriers, pharmaceutical
compositions to be administered can contain minor amounts
of non-toxic auxiliary Substances, such as wetting or emul
Sifying agents, preservatives, and pH buffering agents and
the like, for example sodium acetate or Sorbitan monolau

25

rate.

The composition can be a liquid solution, Suspension,
emulsion, tablet, pill, capsule, Sustained release formulation,
or powder, but not a liposome also containing a protease
inhibitor. For Solid compositions (e.g., powder, pill, tablet,
or capsule forms), conventional non-toxic Solid carriers can
include, for example, pharmaceutical grades of mannitol,
lactose, starch, Sodium saccharine, cellulose, magnesium
carbonate, or magnesium Stearate. The composition can be
formulated as a Suppository, with traditional binders and
carriers such as triglycerides.
The amount of antigen, Such as a clotting factor, effective
in the treatment of a particular disorder or condition, such as
hemophilia, will depend on the nature of the disorder or
condition, and can be determined by standard clinical tech
niques. In addition, in vitro assays can be employed to
identify optimal dosage ranges (see EXAMPLES 7 and 8).
The precise dose to be employed in the formulation will also
depend on the seriousness of the disease or disorder, and
should be decided according to the judgment of the practi
tioner and each subject's circumstances. Effective doses can
be extrapolated from dose-response curves derived from in
vitro or animal model test systems.
The disclosure also provides a pharmaceutical pack or kit
comprising one or more containers filled with one or more
of the ingredients of the pharmaceutical compositions.
Optionally associated with Such container(s) can be a notice
in the form prescribed by a governmental agency regulating
the manufacture, use or sale of pharmaceuticals or biological
products, which notice reflects approval by the agency of
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manufacture, use or sale for human administration. Instruc

tions for use of the composition can also be included.
Administration of Nucleic Acid Molecules

In an embodiment in which a nucleic acid is employed to
allow expression of a nucleic acid in a cell, the nucleic acid
is delivered intracellularly (e.g., by expression from a
nucleic acid vector or by receptor-mediated mechanisms). In
one embodiment, a nucleic acid encodes for an antigen, Such
as a clotting factor.
Various delivery systems for administering a nucleic acid
are known, and include encapsulation in liposomes, micro

The compounds may be administered by any convenient
route, for example by infusion or bolus injection, by absorp
tion through epithelial or mucocutaneous linings (e.g., oral
mucosa, rectal, vaginal and intestinal mucosa, etc.) and may
be administered together with other biologically active
agents. Administration can be systemic or local. Pharma
ceutical compositions can be introduced into the central
nervous system by any Suitable route, including intraven
tricular and intrathecal injection; intraventricular injection
may be facilitated by an intraventricular catheter, for
example, attached to a reservoir, Such as an Ommaya
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fusion of membranes, such as Sendai virus or influenza

virus. The lipids may be any useful combination of known
liposome forming lipids, including cationic lipids, Such as
phosphatidylcholine. Other potential lipids include neutral
lipids, such as cholesterol, phosphatidyl serine, phosphatidyl
glycerol, and the like. For preparing the liposomes, the
procedure described by Kato et al. (J. Biol. Chem. 1991,
266:3361) can be used.
Where the therapeutic molecule is a nucleic acid, admin
istration can be achieved by an appropriate nucleic acid
expression vector which is administered so that it becomes
intracellular, e.g., by use of a retroviral vector (see U.S. Pat.
No. 4,980.286), or by direct injection, or by use of micro
particle bombardment (e.g., a gene gun; Biolistic, Dupont),
or coating with lipids or cell-surface receptors or transfect
ing agents, or by administering it in linkage to a homeobox
like peptide which is known to enter the nucleus (see e.g.,
Joliot et al., Proc. Natl. Acad. Sci. USA 1991, 88:1864-8),
etc. Alternatively, the nucleic acid can be introduced intra
cellularly and incorporated within host cell DNA for expres
Sion, by homologous recombination.
The vector pcDNA, is an example of a method of intro
ducing the foreign cDNA into a cell under the control of a
strong viral promoter (CMV) to drive the expression. How
ever, other vectors can be used (see EXAMPLES 13 and 15).
Other retroviral vectors (such as pRETRO-ON, Clontech),
also use this promoter but have the advantages of entering
cells without any transfection aid, integrating into the
genome of target cells only when the target cell is dividing
(as cancer cells do, especially during first remissions after
chemotherapy) and they are regulated. It is also possible to
turn on the expression of a nucleic acid by administering
tetracycline when these plasmids are used.
Other plasmid vectors, such as pMAM-neo (Clontech) or
pMSG (Pharmacia) use the MMTV-LTR promoter (which
can be regulated with steroids) or the SV10 late promoter
(pSVL, Pharmacia) or metallothionein-responsive promoter
(pBPV. Pharmacia) and other viral vectors, including retro
viruses. Examples of other viral vectors include adenovirus,
AAV (adeno-associated virus), recombinant HSV, poxvi
ruses (vaccinia) and recombinant lentivirus (such as HIV).
These vectors achieve the basic goal of delivering into the
target cell the cDNA sequence and control elements needed
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for transcription. The present disclosure includes all forms
of nucleic acid delivery, including synthetic oligos, naked
DNA, plasmid and viral, integrated into the genome or not.
Having illustrated and described methods for treating
hemophilia A or B by oral administration of a therapeutically
effective amount of F.VIII or F.IX, respectively, it should be
apparent to one skilled in the art that the disclosure can be
modified in arrangement and detail without departing from
Such principles. In view of the many possible embodiments
to which the principles of our disclosure may be applied, it
should be recognized that the illustrated embodiments are
only particular examples of the disclosure and should not be
taken as a limitation on the scope of the disclosure. Rather,
the scope of the disclosure is in accord with the following
claims. We therefore claim as our invention all that comes

5

10

15

within the scope and spirit of these claims.

20. The method of claim 19, wherein the milk is obtained

We claim:

1. A method for increasing hemostasis in a Subject having
hemophilia B in which clotting factor IX (FIX) is deficient
and wherein the subject does not have F.IX inhibitors,
comprising orally administering to the Subject a therapeuti
cally effective amount of the F.IX sufficient to induce oral
tolerance of the F.IX and supply exogenous F.IX to the
Subject, thereby increasing hemoslasis in the Subject and
treating the hemophilia B, wherein the F.IX is not present in
a liposome.
2. The method of claim 1, wherein the hemophilia B is a
result of impaired expression of the F.IX, and the F.IX is
administered as long as the hemophilia B persists.
3. The method of claim 1, wherein increasing hemostasis
comprises decreasing blood clotting time.
4. The method of claim 1, wherein the F.IX is adminis
tered in absence of an anti-immune therapy.
5. The method of claim 1, wherein the therapeutically
effective amount of F.IX is at least 5 mg of F.IX per 1 kg of
Subject daily.
6. The method of claim 1, wherein the therapeutically
effective amount of F.IX is at least 50 mg of F.IX per 1 kg
of subject daily.
7. The method of claim 1, wherein the subject is a

from a non-human transgenic mammal.
21. The method of claim 20, wherein the mammal is a pig.
22. The method of claim 21, wherein the recombinant

F.IX is present at a concentration of about 2 g per liter of the
milk.
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8. The method of claim 7, wherein the mammal is a
45

thereby treating the hemophilia B.
24. A method for orally administering a recombinant F.IX
protein to a subject for treatment of hemophilia B, wherein
the subject does not have inhibitors to FIX, comprising
orally administering milk containing recombinant F.IX pro
tein to the subject at a therapeutically effective amount such
that blood clotting time in the subject is reduced and oral
tolerance of the recombinant F.IX protein is induced,
thereby treating the hemophilia B.
25. A method of increasing hemostasis in a mammal
having hemophilia B, comprising orally administering to the
mammal 5-50 mg/kg/day of factor IX, wherein factor IX is
not present in a liposome, and wherein the factor IX induces
oral tolerance of the factor IX and Supplies exogenous factor
IX to the mammal, thereby increasing hemostasis in the
mammal.
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12. The method of claim 1, wherein oral administration is

achieved by feeding the subject a therapeutically effective
amount of the clotting factor.
13. The method of claim 12, wherein the F.IX is a
55

mammal.

14. The method of claim 1, wherein the F.IX is present in
a pharmaceutically effective carrier.
15. The method of claim 14, wherein the pharmaceuti
cally effective carrier is water.
16. The method of claim 14, wherein the pharmaceuti
cally effective carrier is milk.
17. A method for increasing hemostasis and inducing oral
tolerance in a Subject having hemophilia B in which clotting

orally administering the milk in which the F.IX has been
expressed to the subject at a therapeutically effective
amount Such that blood cloning time in the Subject is
reduced and oral tolerance of the FIX is induced,

human.

recombinant F.IX present in milk of a non-human transgenic

23. A method for orally administering a recombinant
clotting factor IX (F.IX) to a subject for treatment of
hemophilia B in which F.IX is deficient wherein the subject
does not have inhibitors to FIX, comprising:
expressing the recombinant F.IX in a non-human mammal
such that the F.IX is expressed in milk of the mammal;
and

mammal.

9. The method of claim 1, wherein the F.IX is present in
milk obtained from a non-human transgenic mammal
expressing recombinant F.IX.
10. The method of claim 9, wherein the mammal is a pig.
11. The method of claim 3, wherein the blood clotting
time is measured using an activated partial thromboplastin
time (APTT) assay.
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factor IX (F.IX) is deficient and wherein the subject does not
have F.IX inhibitors, consisting of orally administering to
the subject the therapeutically effective amount of F.IX and
at least one pharmaceutically acceptable carrier which is not
a liposome.
18. A method for orally administering a recombinant
clotting factor IX (F.IX) to a subject for treatment of
hemophilia B in which F.IX is deficient, wherein the subject
does not have inhibitors to FIX, comprising orally admin
istering a milk containing recombinant F.IX to the Subject at
a therapeutically effective amount Such that hemostasis in
the subject is increased and oral tolerance of F.IX is induced,
thereby treating the hemophilia B.
19. The method of claim 18, wherein the milk comprises
at least 2 g recombinant clotting factor IX per liter of milk.

26. A method of increasing hemostasis in a mammal
having hemophilia B, comprising orally administering to the
mammal every other day 5-50 mg/kg of factor IX, wherein
factor IX is not present in a liposome, and wherein the factor
IX induces oral tolerance of the factor IX and supplies
exogenous factor IX to the mammal, thereby increasing
hemostasis in the mammal.

27. The method of claim 25, wherein the factor IX is

recombinant factor IX present in milk of a non-human
transgenic mammal.
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28. The method of claim 26, wherein the factor IX is

recombinant factor IX present in milk of a non-human
transgenic mammal.
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